<SEC-DOCUMENT>0001047469-20-002368.txt : 20200416
<SEC-HEADER>0001047469-20-002368.hdr.sgml : 20200416
<ACCEPTANCE-DATETIME>20200416172825
ACCESSION NUMBER:		0001047469-20-002368
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200528
FILED AS OF DATE:		20200416
DATE AS OF CHANGE:		20200416
EFFECTIVENESS DATE:		20200416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980505495
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37852
		FILM NUMBER:		20797203

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2241314zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#20ZAD70401_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> PROTAGONIST THERAPEUTICS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=475441,FOLIO='blank',FILE='DISK135:[20ZAD1.20ZAD70401]BA70401A.;4',USER='MPAPADI',CD='15-APR-2020;21:46' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g494085.jpg" ALT="LOGO" WIDTH="366" HEIGHT="91">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7707&nbsp;Gateway
Blvd., Suite&nbsp;140<BR>
Newark, California 94560 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>To Be Held On May&nbsp;28, 2020  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Dear Stockholder: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cordially invited to attend the Annual Meeting of Stockholders (the&nbsp;"Annual Meeting") of Protagonist Therapeutics,&nbsp;Inc., a Delaware corporation
(the&nbsp;"Company"). The meeting will be held virtually via live webcast at www.virtualshareholdermeeting.com/PTGX2020 on Thursday, May&nbsp;28, 2020 at 10:00&nbsp;a.m. PDT for the following
purposes: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><B>1.</B></FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>To elect the Company's Board of Directors two Class&nbsp;I nominees, Sarah Noonberg, M.D., Ph.D. and Dinesh
V. Patel, Ph.D., to the Board of Directors to hold office until the 2023 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier resignation
or removal.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><B>2.</B></FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>To ratify the selection by the Audit Committee of the Board of Directors of Ernst&nbsp;&amp; Young&nbsp;LLP
as the independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><B>3.</B></FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>To conduct any other business properly brought before the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
items of business are more fully described in the Proxy Statement accompanying this&nbsp;Notice. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have decided to hold the Annual Meeting virtually this year due to the public health impact of the COVID-19 outbreak and to support the health and well-being of our employees,
stockholders and partners. We believe that hosting a virtual meeting under the current environment will enable greater stockholder attendance and participation and improve our ability to communicate
more effectively with our stockholders. Online check-in will begin at 9:45&nbsp;a.m. PDT and you should allow ample time for the check-in procedures. You will not be able to attend the Annual
Meeting in person. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
record date for the Annual Meeting is March&nbsp;31, 2020. Only stockholders of record at the close of business on that date may vote at the meeting or any adjournment thereof. To
participate in the meeting, you must have your 16-digit control number shown on your Notice of Internet Availability of Proxy Materials or on the instructions that accompanied your proxy materials. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>By
Order of the Board of Directors </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>/s/ Dinesh V. Patel<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Dinesh V. Patel, Ph.D.<BR>
President and Chief Executive Officer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>Newark,
California<BR>
April&nbsp;16, 2020 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>You are cordially invited to attend the meeting virtually via live webcast. Whether or not you expect to attend the virtual meeting, you are urged to vote and submit your proxy
by following the voting procedures described in the proxy card. A return envelope (which is postage prepaid if mailed in the United&nbsp;States) has been provided for your convenience. Even if you
have voted by proxy, you may still vote during the virtual meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting,
you must obtain a proxy issued in your name from that record&nbsp;holder.</B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=183702,FOLIO='blank',FILE='DISK135:[20ZAD1.20ZAD70401]BC70401A.;11',USER='JDAY',CD='16-APR-2020;12:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_be70401_1_1"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g494085.jpg" ALT="LOGO" WIDTH="366" HEIGHT="91">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7707&nbsp;Gateway
Blvd., Suite&nbsp;140<BR>
Newark, California 94560 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT<BR>
FOR THE 2020 ANNUAL MEETING OF STOCKHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Thursday, May&nbsp;28, 2020  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="be70401_questions_and_answers___be702553"> </A>
<A NAME="toc_be70401_1"> </A>
<BR>  QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Why did I receive a notice regarding the availability of proxy materials on the&nbsp;internet?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to rules adopted by the Securities and Exchange Commission (the&nbsp;"SEC"), we have elected to provide access to our proxy
materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the&nbsp;"Notice") because the Board of Directors (the&nbsp;"Board") of Protagonist
Therapeutics,&nbsp;Inc. (sometimes referred to as the "Company" or "Protagonist") is soliciting your proxy to vote at the 2020 Annual Meeting of Stockholders (the&nbsp;"Annual Meeting"), including
at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set
of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the&nbsp;Notice. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to mail the Notice on or about April&nbsp;16, 2020 to all stockholders of record entitled to vote at the Annual&nbsp;Meeting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Will I receive any other proxy materials by mail?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may send you a proxy card, along with a second Notice, on or after April&nbsp;26,&nbsp;2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> How do I attend and participate in the Annual Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The meeting will be held virtually via live webcast at www.virtualshareholdermeeting.com/PTGX2020 on Thursday, May&nbsp;28, 2020 at
10:00&nbsp;a.m. PDT. Information on how to vote online at the Annual Meeting is discussed below. To attend the meeting, you will need the 16-digit control number included in your Notice or on the
instructions that accompanied your proxy materials. Online check-in will begin at 9:45&nbsp;a.m. PDT and should allow ample time for the check-in procedures. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Why is the 2020 Annual Meeting being held virtually?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Annual Meeting is being held virtually this year due to the public health impact of the COVID-19 outbreak and to support the health
and well-being of our partners, employees, and stockholders. You will not be able to attend the Annual Meeting in person. The virtual meeting will provide the same rights and advantages of a physical
meeting. Stockholders will be able to submit questions online during the meeting, providing our stockholders with the opportunity for meaningful engagement with the Company. Questions must comply with
the meeting rules of conduct; the rules of conduct will be posted on the virtual meeting web portal. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Who can vote at the Annual Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on March&nbsp;31, 2020 will be entitled to vote at the Annual Meeting. On this
record date, there were 27,434,705&nbsp;shares of common stock outstanding and entitled to&nbsp;vote. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> Stockholder of Record: Shares Registered in Your Name  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If on March&nbsp;31, 2020 your shares were registered directly in your name with Protagonist's transfer agent, American Stock
Transfer&nbsp;&amp; Trust Company,&nbsp;LLC, then you are a stockholder of record. As a stockholder of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=483956,FOLIO='1',FILE='DISK135:[20ZAD1.20ZAD70401]BE70401A.;20',USER='LPAULIN',CD='16-APR-2020;14:37' -->
<A NAME="page_be70401_1_2"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>record,
you may vote online at the Annual Meeting or vote by proxy. Whether or not you plan to attend the Annual Meeting, we urge you to fill out and return the enclosed proxy card to ensure your vote
is&nbsp;counted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> Beneficial Owner: Shares Registered in the Name of a Broker or Bank  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If on March&nbsp;31, 2020, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or
other similar organization, then you are the beneficial owner of shares held in "street name" and the Notice is being forwarded to you by that organization. The organization holding your account is
considered to be the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares
in your account. You are also invited to attend the Annual Meeting virtually via live webcast. However, since you are not the stockholder of record, you may not vote your shares online at the virtual
meeting unless you request and obtain a valid proxy from your broker or other&nbsp;agent. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> What am I voting on?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are two matters scheduled for a vote:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Proposal No.&nbsp;1&nbsp;&#151;&nbsp;To elect the two Class&nbsp;I nominees named herein to our
Board of Directors to hold office until the 2023 Annual Meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier resignation or removal; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Proposal No.&nbsp;2&nbsp;&#151;&nbsp;To ratify the selection by the Audit Committee of the Board
of Directors of Ernst&nbsp;&amp; Young&nbsp;LLP as the independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31, 2020. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this proxy statement, we are not aware of any other matters that will be presented for consideration at the Annual&nbsp;Meeting. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> What if another matter is properly brought before the meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly
brought before the meeting, it is the intention of
the persons named in the accompanying proxy to vote on those matters in accordance with their best&nbsp;judgment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> How do I vote?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may either vote "For" all the nominees to the Board or you may "Withhold" your vote for any nominee you specify. For the
ratification of selection by the Audit Committee of the Board of Ernst&nbsp;&amp; Young&nbsp;LLP as the independent registered public accounting firm of the Company for the fiscal year ending
December&nbsp;31, 2020, you may vote "For" or "Against" or abstain from&nbsp;voting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
procedures for voting are fairly simple: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> Stockholder of Record: Shares Registered in Your Name  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you may vote online during the webcast of the Annual Meeting, vote by proxy over the telephone,
vote by proxy through the internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the meeting online, we
urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote online even if you have already voted by&nbsp;proxy. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>To vote online at the Annual Meeting you must be present via live webcast. To vote live during the meeting, please visit
www.virtualshareholdermeeting.com/PTGX2020 and have available the 16-digit control number included in your Notice or on the instructions that accompanied your proxy materials. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>To vote using the proxy card, simply complete, sign and date the proxy card that may be delivered and return it promptly
in the envelope provided. If you return your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=73296,FOLIO='2',FILE='DISK135:[20ZAD1.20ZAD70401]BE70401A.;20',USER='LPAULIN',CD='16-APR-2020;14:37' -->
<A NAME="page_be70401_1_3"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>To vote over the telephone prior to the Annual Meeting, dial toll-free 1-800-690-6903&nbsp;using a telephone and follow
the recorded instructions. You will be asked to provide the company number and control number from the Notice. Your telephone vote must be received by 11:59&nbsp;p.m., Eastern Time on May&nbsp;27,
2020 to be counted. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>To vote through the internet prior to the Annual Meeting, go to www.proxyvote.com to complete an electronic proxy card.
You will be asked to provide the company number and control number from the Notice. Your internet vote must be received by 11:59&nbsp;p.m., Eastern Time on May&nbsp;27, 2020 to be counted. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> Beneficial Owner: Shares Registered in the Name of Broker or Bank  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a Notice
containing voting instructions from that organization rather than from Protagonist. Simply follow the voting instructions in the Notice to ensure that your vote is counted. To vote online at the
Annual Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker or bank included with these proxy materials or contact your broker or bank
to request a proxy&nbsp;form. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
<!-- BOXING PARAGRAPH(S) -->
 </FONT></P>
<DIV style="width:100%;border:solid #000000 1pt;margin-right:1pt;padding-top:9pt;padding-right:11pt;padding-bottom:10pt;padding-left:12pt;">

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Internet proxy voting may be provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy
vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone
companies.</B></FONT></P>
 <p style="font-family:times;margin-bottom:-11pt;"></p>
</DIV>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> How many votes do I have?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On each matter to be voted upon, you have one vote for each share of common stock you own as of March&nbsp;31,&nbsp;2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> What happens if I do not vote?  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> Stockholder of Record: Shares Registered in Your Name  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record and do not vote by completing your proxy card, by telephone, through the internet or online at the
Annual Meeting, your shares will not be&nbsp;voted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> Beneficial Owner: Shares Registered in the Name of Broker or Bank  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a beneficial owner of shares registered in the name of your broker, bank or other nominee (sometimes referred to as shares
held in "street name"), and you do not provide the broker or other nominee that holds your shares with voting instructions, the question of whether your broker or nominee will still be able to vote
your shares depends on whether the New York Stock Exchange ("NYSE") deems the particular proposal is a "routine" matter. Brokers and nominees can use their discretion to vote "uninstructed" shares
with respect to matters that are considered to be "routine," but not with respect to "non-routine" matters. "Non-routine" matters are matters that may substantially affect the rights or privileges of
stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation, and certain corporate governance proposals, even if management-supported.
Proposal&nbsp;1 is considered "non-routine" and Proposal&nbsp;2 is considered "routine." </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> What if I return a proxy card or otherwise vote but do not make specific choices?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted,
as&nbsp;applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>"For" the election of the two Class&nbsp;I nominees for director; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>"For" the ratification of Ernst&nbsp;&amp; Young&nbsp;LLP as the independent registered public accounting firm of the
Company for its fiscal year ending December&nbsp;31,&nbsp;2020. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=5,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=857891,FOLIO='3',FILE='DISK135:[20ZAD1.20ZAD70401]BE70401A.;20',USER='LPAULIN',CD='16-APR-2020;14:37' -->
<A NAME="page_be70401_1_4"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any other matter is properly presented at the Annual Meeting, your proxyholder (one&nbsp;of the individuals named on your proxy card) will vote your shares using his or her
best&nbsp;judgment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Who is paying for this proxy solicitation?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, our directors and employees may also
solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse
brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> What does it mean if I receive more than one Notice?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the
voting instructions on the Notices to ensure that all of your shares are&nbsp;voted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Can I change my vote after submitting my proxy?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> Stockholder of Record: Shares Registered in Your Name  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your shares, you may
revoke your proxy in any one of the following&nbsp;ways:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>You may submit another properly completed proxy card with a later date. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>You may grant a subsequent proxy by telephone or through the internet. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>You may send a timely written notice that you are revoking your proxy to Protagonist's Corporate Secretary at
7707&nbsp;Gateway Blvd., Suite&nbsp;140, Newark, California 94560. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>You may attend the Annual Meeting and vote online by visiting www.virtualshareholdermeeting.com/PTGX2020. To attend the
meeting, you will need the 16-digit control number included in your Notice or on the instructions that accompanied your proxy materials. Simply attending the meeting will not, by itself, revoke your
proxy. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
most current proxy card or telephone or internet proxy is the one that is&nbsp;counted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> Beneficial Owner: Shares Registered in the Name of Broker or Bank  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker
or&nbsp;bank. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> When are stockholder proposals and director nominations due for next year's Annual&nbsp;Meeting?  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be considered for inclusion in next year's proxy materials, your proposal must be submitted in writing by December&nbsp;17, 2020,
to Protagonist's Corporate Secretary at 7707&nbsp;Gateway Blvd., Suite&nbsp;140, Newark, California 94560. If you wish to submit a proposal (including a director nomination) at the meeting that is
not to be included in next year's proxy materials, you must provide specified information in writing to our Corporate Secretary at the address above no earlier than January&nbsp;28, 2021 and no
later than February&nbsp;27, 2021; provided, however, that if our 2021 Annual Meeting of Stockholders is held before April&nbsp;28, 2021, or after June&nbsp;27, 2021, notice by the stockholder
to be timely must be received no earlier than the close of business on the 120<SUP>th</SUP>&nbsp;day prior to such Annual Meeting and not later than the close of business on the later of the
90<SUP>th</SUP>&nbsp;day prior to such Annual Meeting or the tenth (10<SUP>th</SUP>) day following the day on which public announcement of the date of such meeting is first made. You are also
advised to review our Amended and Restated Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> How are votes counted?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes will be counted by the inspector of election appointed for the meeting, who will separately count, (i)&nbsp;for the proposal to
elect directors, votes "For," "Withhold" and broker non-votes; and (ii)&nbsp;with respect to Proposal 2 and any other proposals, votes "For" and "Against," abstentions and, if applicable, broker
non-votes. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=6,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=297961,FOLIO='4',FILE='DISK135:[20ZAD1.20ZAD70401]BE70401A.;20',USER='LPAULIN',CD='16-APR-2020;14:37' -->
<A NAME="page_be70401_1_5"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Abstentions
will be counted towards the vote total for Proposal 2 and will have the same effect as "Against" votes. Broker non-votes have no effect and will not be counted towards the vote total for
any&nbsp;proposal. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> What are "broker non-votes"?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As discussed above, when a beneficial owner of shares held in "street name" does not give instructions to the broker or nominee holding
the shares as to how to vote on matters deemed to be "non-routine," the broker or nominee cannot vote the shares. These unvoted shares are counted as "broker non-votes." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> How many votes are needed to approve each proposal?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="24%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="24%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="130pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="106pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:31pt;"><FONT SIZE=1><B>Proposal<BR>
Number

<!-- COMMAND=ADD_SCROPPEDRULE,31pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Proposal Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vote Required for Approval </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Effect of<BR>
Abstentions </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Effect of Broker<BR>
Non-Votes </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Election of Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Nominees receiving the most "For" votes; withheld votes will have no effect.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Under plurality voting, there are no abstentions.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>None</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ratification of the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as the Company's independent registered public accounting firm
for fiscal year ending December&nbsp;31, 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>"For" votes from the holders of a majority of shares present online during the virtual meeting or represented by proxy and
entitled to vote on the matter.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Against</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p align=left style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Not applicable<SUP>(1)</SUP></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
proposal is considered to be a "routine" matter under applicable rules. Accordingly, if you hold your shares in "street name" and do not provide voting
instructions to your broker, bank or other agent that holds your shares, your broker, bank or other agent has discretionary authority under the NYSE rules to vote your shares on this&nbsp;proposal. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><B> What is the quorum requirement?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding a majority of the
outstanding shares entitled to vote are present at the meeting online or represented by proxy. On the record date, there were 27,434,705&nbsp;shares outstanding and entitled to vote. Thus, the
holders of 13,717,353&nbsp;shares must be present online during the virtual meeting or represented by proxy at the Annual Meeting to have a&nbsp;quorum. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
shares will be counted towards the quorum only if you submit a valid proxy (or&nbsp;one is submitted on your behalf by your broker, bank or other nominee) or if you vote online at
the meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the chairperson of the meeting or the holders of a majority of shares present at
the meeting online or represented by proxy may adjourn the meeting to another&nbsp;date. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> How can I find out the results of the voting at the Annual Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a Current
Report on Form&nbsp;8-K that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file&nbsp;a Current Report on
Form&nbsp;8-K within four business days after the meeting, we intend to file&nbsp;a Current Report on Form&nbsp;8-K to&nbsp;publish preliminary results and, within four business days after the
final results are known to us, file an additional Current Report on Form&nbsp;8-K to&nbsp;publish the final&nbsp;results. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> What proxy materials are available on the internet?  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The annual report to stockholders is available at www.proxyvote.com. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=7,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=751751,FOLIO='5',FILE='DISK135:[20ZAD1.20ZAD70401]BE70401A.;20',USER='LPAULIN',CD='16-APR-2020;14:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_da70401_1_6"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da70401_proposal_1_election_of_directors"> </A>
<A NAME="toc_da70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 1    <BR>    <BR>    ELECTION OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Protagonist's Board is divided into three classes. Each class consists, as nearly as possible, of one-third of the total number of
directors, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board to fill a
vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director's successor is duly
elected and&nbsp;qualified. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board presently has seven members. There are two directors in the class whose term of office expires in 2020. Two nominees are recommended for election by the Nominating and
Corporate Governance Committee of the Board. Dr.&nbsp;Noonberg and Dr.&nbsp;Patel are currently directors of the Company and were previously elected by the stockholders. If elected at the Annual
Meeting, each of these nominees would serve until the 2023 Annual Meeting and until his or her successor has been duly elected and qualified, or, if sooner, until the director's death, resignation or
removal. It is the Company's policy to encourage the directors and nominees for director to attend the Annual Meeting. All of the directors attended the 2019 Annual Meeting of Stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors
are elected by a plurality of the votes of the holders of shares present online during the virtual meeting or represented by proxy and entitled to vote on the election of
directors. Accordingly, the two nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld,
for the election of the two nominees named below. If any nominee becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for that nominee will
instead be voted for the election of a substitute nominee proposed by Protagonist. Each person nominated for election has agreed to serve if elected. The Company's management has no reason to believe
that any nominee will be unable to&nbsp;serve. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
brief biographies below include information, as of the date of this proxy statement, regarding the specific and particular experience, qualifications, attributes or skills of each
nominee for director. In addition, following the biographies of the nominees are the biographies of Class&nbsp;II and Class&nbsp;III directors containing information regarding each director
continuing to serve on the&nbsp;Board. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> NOMINEES FOR ELECTION TO CLASS I FOR A THREE-YEAR TERM EXPIRING AT THE 2023 ANNUAL MEETING  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Sarah Noonberg, M.D., Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Noonberg, 52, has served as a member of the Board since December&nbsp;2017. Since May&nbsp;2019, Dr.&nbsp;Noonberg has
provided Chief Medical Officer consultant services to multiple private biotechnology companies. She previously served as Chief Medical Officer of Nohla Therapeutics, developer of universal,
off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, from May&nbsp;2018 to May&nbsp;2019. Prior to joining Nohla Therapeutics, she served as the
Chief Medical Officer of Prothena Corporation&nbsp;plc, a biotechnology company, from May&nbsp;2017 to March&nbsp;2018. Prior to joining Prothena, Dr.&nbsp;Noonberg served from
August&nbsp;2015 to March&nbsp;2017 as Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals&nbsp;Inc., a biotechnology company, where she was responsible for
development strategy and execution across a diverse clinical portfolio. From 2007 to August&nbsp;2015, she held several positions at Medivation,&nbsp;Inc., a biopharmaceutical company, where, as
Senior Vice President of Early Development and Vice President of Clinical Development, she led programs across all phases of development, including enzalutamide (XTANDI) for the treatment of
chemotherapy-na&iuml;ve metastatic prostate cancer. Dr.&nbsp;Noonberg also held several clinical positions between 2004 and 2007 at Chiron Corporation, where she led the clinical
development of compounds in infectious disease and pulmonary indications. She has served on the board of directors of Neoleukin Therapeutics, a public biopharmaceutical company, since August 2019.
Dr.&nbsp;Noonberg earned her M.D. at the University of California, San Francisco, her Ph.D. in Bioengineering at the University of California, Berkeley, and her B.S. at Dartmouth College. She is a
board-certified internist and completed her residency at Johns Hopkins Hospital. From 2002 to 2018, she was a part-time hospitalist, working as an attending physician treating a broad range of
inpatient and critical care patients. The Company believes that because of her executive business experience as well as her extensive medical knowledge and clinical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=38879,FOLIO='6',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_da70401_1_7"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>development
and regulatory expertise, Dr.&nbsp;Noonberg is well positioned to make valuable contributions and provide valuable guidance to the&nbsp;Board. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Dinesh V. Patel, Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Patel, age 63, has served as a member of the Company's Board and as the Company's President and Chief Executive Officer
since December&nbsp;2008. Dr.&nbsp;Patel has more than 35&nbsp;years of executive, entrepreneurial and scientific experience spanning the pharmaceutical, biotechnology and biopharmaceutical
industries. Prior to joining the Company, Dr.&nbsp;Patel served from 2006 to 2008 as the President and Chief Executive Officer of Ar&ecirc;te Therapeutics, a privately held company focused
on the development of novel drugs for metabolic syndrome. Prior to that, he was President, Chief Executive Officer and Co-Founder of Miikana Therapeutics, an oncology-based company, from 2003 until it
was acquired by Entremed (later renamed CASI Pharmaceuticals) in 2005. Prior to Miikana, Dr.&nbsp;Patel held positions of increasing responsibility at Versicor (later renamed Vicuron and which was
acquired by Pfizer in 2005), from 1996 to 2003, most recently as Senior Vice President of Drug Discovery and Licensing. Prior to Vicuron, Dr.&nbsp;Patel was a director of chemistry at the
combinatorial chemistry company Affymax, from 1993 to 1996. Dr.&nbsp;Patel was a medicinal chemist at BristolMyers Squibb from 1985 to 1993. Dr.&nbsp;Patel received his Ph.D. in Chemistry from
Rutgers University, New&nbsp;Jersey and his B.S. in Industrial Chemistry from S. P. University, Vallabh Vidyanagar, India. The Company believes that because of his expertise, extensive knowledge of
the Company and experience as an executive officer of biotechnology companies, Dr.&nbsp;Patel is able to make valuable contributions to the&nbsp;Board. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da70401_the_board_of_directors_recomme__the02782"> </A>
<A NAME="toc_da70401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  THE BOARD OF DIRECTORS RECOMMENDS<BR>  A VOTE IN FAVOR OF EACH NAMED NOMINEE.    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the two Class&nbsp;I nominees for director, Protagonist has five other directors who will continue in office after the
Annual Meeting with terms expiring in 2021 and 2022. The following includes a brief biography of each director composing the remainder of the Board with terms expiring as shown, with each biography
including information regarding the experience, qualifications, attributes or skills that caused the Nominating and Corporate Governance Committee and the Board to determine that the applicable
director should serve as a member of the&nbsp;Board. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> CLASS II DIRECTORS CONTINUING IN OFFICE UNTILTHE 2021 ANNUAL MEETING  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Chaitan Khosla, Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Khosla, 55, has served as a member of the Board since October&nbsp;2014. Dr.&nbsp;Khosla was previously a scientific
founder of Sitari Pharmaceuticals in 2013 until it was acquired by GlaxoSmithKline in 2019. Prior to Sitari Pharmaceuticals, Dr.&nbsp;Khosla was a founder and a member of the board of directors of
Alvine Pharmaceuticals from 2005 until it was acquired by Immunogenics&nbsp;LLC in 2016, and of Kosan Biosciences from 1995 until it was acquired by BristolMyers Squibb in
2008.&nbsp;Dr.&nbsp;Khosla has been a Professor of Chemical Engineering and Chemistry at Stanford University since 2001 and has been a faculty member since 1992. Since 2013, he has served as the
founding Director of Stanford ChEM-H. Dr.&nbsp;Khosla is an elected member of the American Academy of Arts&nbsp;&amp; Sciences and the National Academy of Engineering. He is the recipient of several
awards, including the 1999 Alan T. Waterman award by the National Science Foundation, the 1999 Eli Lilly Award in biological chemistry and the 2000 ACS Award in Pure Chemistry. Dr.&nbsp;Khosla is
the author of over 350&nbsp;publications and is an inventor on over 75&nbsp;issued U.S.&nbsp;patents. Dr.&nbsp;Khosla received a Ph.D. from the California Institute of Technology. The Company
believes that Dr.&nbsp;Khosla is qualified to serve on the Board because of his experience as a founder, consultant and director of biotechnology companies and his expertise in the biotechnology
field. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> William D. Waddill  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Waddill, 63, has served as a member of the Board since July&nbsp;2016. From April&nbsp;2014 to December&nbsp;2016,
Mr.&nbsp;Waddill served as Senior Vice President and Chief Financial Officer, Treasurer and Secretary of Calithera Biosciences,&nbsp;Inc., a biotechnology company. From October&nbsp;2007 to
March&nbsp;2014, Mr.&nbsp;Waddill served as Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=9,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=364079,FOLIO='7',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_da70401_1_8"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>From
October&nbsp;2006 to September&nbsp;2007, Mr.&nbsp;Waddill served as the Senior Vice President, Chief Financial Officer of Ilypsa,&nbsp;Inc., a biotechnology company that was acquired in
2007 by Amgen,&nbsp;Inc. From February&nbsp;2000 to September&nbsp;2006, Mr.&nbsp;Waddill served as a Principal at Square One Finance, a financial consulting business. From
December&nbsp;1996 to February&nbsp;2000, Mr.&nbsp;Waddill served as Senior Director of Finance and Administration
at Exelixis,&nbsp;Inc., a biotechnology company. He has served as a director of Arrowhead Pharmaceuticals, a public company, since January&nbsp;2018. Mr.&nbsp;Waddill received a B.S. in
Accounting from the University of Illinois, Chicago, and a certification as a public accountant, which is currently inactive, after working at PricewaterhouseCoopers&nbsp;LLP and
Deloitte&nbsp;LLP. The Company believes that Mr.&nbsp;Waddill is qualified to serve on the Board because of his financial expertise and extensive experience in the biotechnology field. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Lewis T. "Rusty" Williams, M.D., Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Williams, 70, has served as a member of the Board since June&nbsp;2017. He has served as Chairman and Chief Executive
Officer of Walking Fish Therapeutics, a biotechnology start-up company, since February 2019. Dr.&nbsp;Williams has also served as a venture partner of Quan Capital,&nbsp;LLP, a healthcare-focused
venture capital firm, since October&nbsp;2018. Dr.&nbsp;Williams founded and served as a director of Five Prime Therapeutics,&nbsp;Inc., a public biotechnology company, from January&nbsp;2002
until January&nbsp;2020, and served as its President and Chief Executive Officer from April&nbsp;2011 to December&nbsp;2017. Previously, Dr.&nbsp;Williams spent seven years at Chiron
Corporation ("Chiron") a biopharmaceutical company, now known as Novartis Vaccines and Diagnostics,&nbsp;Inc., most recently as its Chief Scientific Officer. He also served on Chiron's board of
directors from 1999 to 2001. Prior to joining Chiron, Dr.&nbsp;Williams was a professor of medicine at the University of California, San Francisco, and served as Director of the University's
Cardiovascular Research Institution and Daiichi Research Center. Dr.&nbsp;Williams also has served on the faculties of Harvard Medical School and Massachusetts General Hospital and co-founded COR
Therapeutics,&nbsp;Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences.
Dr.&nbsp;Williams has served as a member of the board of directors of Neoleukin Pharmaceuticals, a public biopharmaceutical company, since September 2019. He was previously a member of the board of
directors of COR Therapeutics,&nbsp;Inc., and Beckman Coulter,&nbsp;Inc., each of which was a public company during his service as a director. Dr.&nbsp;Williams also currently serves on the
board of directors of a privately-held company. He received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University. The Company believes that Dr.&nbsp;Williams' extensive
experience in drug discovery and development, his executive experience with several pharmaceutical companies and his service as a director of other publicly-traded healthcare companies have provided
him the qualifications, skills and financial expertise to serve on the&nbsp;Board. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> CLASS III DIRECTORS CONTINUING IN OFFICE UNTIL THE 2022 ANNUAL MEETING  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Harold E. Selick, Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Selick, 65, has served on the Board since February&nbsp;2009. Dr.&nbsp;Selick has served as Vice Chancellor of Business
Development, Innovation and Partnerships at the University of California,
San Francisco, since April&nbsp;2017. He has been a Venture Partner at Mission Bay Capital since 2018. Previously, he was the Chief Executive Officer of Threshold Pharmaceuticals,&nbsp;Inc., a
biotechnology company, from June&nbsp;2002 until the company's merger with Molecular Templates&nbsp;Inc. in April&nbsp;2017. From June&nbsp;2002 until July&nbsp;2007, Dr.&nbsp;Selick was
also a Venture Partner of Sofinnova Ventures,&nbsp;Inc., a venture capital firm. From January&nbsp;1999 to April&nbsp;2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology
company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome&nbsp;plc, most recently as Vice President of Research. Prior to
working at Affymax he held scientific positions at Protein Design Labs,&nbsp;Inc. and Anergen,&nbsp;Inc. Dr.&nbsp;Selick serves as Chairman of the board of directors of Molecular
Templates,&nbsp;Inc., a public company. Dr.&nbsp;Selick previously served as Lead Director and then Chairman of PDL, a public company, from 2009 to December&nbsp;2019, and served as Chairman of
the board of directors of Threshold Pharmaceuticals,&nbsp;Inc., a public company, until it merged with Molecular Templates&nbsp;Inc. in April&nbsp;2017. Dr.&nbsp;Selick received his B.A. in
Biophysics and Ph.D. in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of
California, San Francisco. The Company believes that because of his broad experience in building and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=10,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=449480,FOLIO='8',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_da70401_1_9"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>running
both private and public companies and serving on the boards of directors of a variety of biotechnology companies, Dr.&nbsp;Selick is well positioned to provide guidance and insight to the
Board and management&nbsp;team. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Bryan Giraudo  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Giraudo, age 44,&nbsp;has served as a member of the Board since May&nbsp;2018. Mr.&nbsp;Giraudo has also served as
Chief Financial Officer of Gossamer Bio, a publicly-held San Diego-based biotechnology company, since May&nbsp;2018. Prior to joining Gossamer Bio, he was Senior Managing Director at Leerink
Partners, a healthcare-focused investment bank, from 2009 to April&nbsp;2018. Before joining Leerink, Mr.&nbsp;Giraudo was a Managing Director with Merrill Lynch. Mr.&nbsp;Giraudo received his
B.A. from Georgetown University. The Company believes Mr.&nbsp;Giraudo is qualified to serve on the Board because of his extensive experience in the investment banking field, financial expertise and
experience in the biotechnology field. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da70401_information_regarding_the_boar__inf02787"> </A>
<A NAME="toc_da70401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> INDEPENDENCE OF THE BOARD OF DIRECTORS  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As required under the Nasdaq Stock Market ("Nasdaq") listing standards, a majority of the members of a listed company's Board must
qualify as "independent," as affirmatively determined by the Board. The Board consults with the Company's counsel to ensure that the Board's determinations are consistent with relevant securities and
other laws and regulations regarding the definition of "independent," including those set forth in pertinent listing standards of Nasdaq, as in effect from time to&nbsp;time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent
with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and the Company,
its senior management and its independent auditors, the Board has affirmatively determined that the following six directors, including the current nominees for the Board, are independent directors
within the meaning of the applicable Nasdaq listing standards: Mr.&nbsp;Giraudo, Dr.&nbsp;Khosla, Dr.&nbsp;Noonberg, Dr.&nbsp;Selick, Mr.&nbsp;Waddill, and Dr.&nbsp;Williams.
Dr.&nbsp;Shanafelt, who served as a director until the 2019 Annual Meeting, was determined to be independent during the time he served on the Board. In making this determination, the Board found
that none of these directors or nominees for director had a material or other disqualifying relationship with the Company. Dr.&nbsp;Patel is not considered independent because he is an executive
officer of the&nbsp;Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
making those independence determinations, the Board took into account certain relationships and transactions that occurred in the ordinary course of business between the Company and
entities with which some of its directors are or have been affiliated. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> BOARD LEADERSHIP STRUCTURE  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has an independent Chairperson, Dr.&nbsp;Selick, who has authority, among other things, to call and preside over Board
meetings, including meetings of the independent directors, to set meeting agendas and to determine materials to be distributed to the Board. Accordingly, the Chairperson of the Board ("Chairperson")
has substantial ability to shape the work of the Board. The Company believes that separation of the positions of Chairperson and Chief Executive Officer reinforces the independence of the Board in its
oversight of the business and affairs of the Company. In addition, the Company believes that having an independent Chairperson creates an environment that is more conducive to objective evaluation and
oversight of management's performance, increasing management accountability and improving the ability of the Board to monitor whether management's actions are in the best interests of the Company and
its stockholders. As a result, the Company believes that having an independent Chairperson can enhance the effectiveness of the Board as a&nbsp;whole. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> ROLE OF THE BOARD IN RISK OVERSIGHT  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has responsibility for the oversight of the Company's risk management processes and, either as a whole or through its
committees, regularly discusses with management the Company's major risk exposures, their potential impact on the Company's business and the steps taken to manage them. The risk oversight process
includes receiving regular reports from Board committees and members of senior management to enable the Board to understand the Company's risk identification, risk management and risk mitigation </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=11,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=306313,FOLIO='9',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_da70401_1_10"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>strategies
with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic, and reputational risk. The Audit Committee reviews information regarding
liquidity and operations and oversees the Company's management of financial risks. Periodically, the Audit Committee reviews the Company's policies with respect to risk assessment, risk management,
loss prevention, and regulatory compliance. Oversight by the Audit Committee includes direct communication with the Company's external auditors, and discussions with management regarding significant
risk exposures and the actions management has taken to limit, monitor or control such exposures. The Compensation Committee is responsible for assessing whether any of the Company's compensation
policies or programs has the potential to encourage excessive risk taking. The Nominating and Corporate Governance Committee manages risks associated with the independence of the Board, corporate
disclosure practices, and potential conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board is regularly
informed through committee reports about such risks. Matters of significant strategic risk are considered by the Board as a&nbsp;whole. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regarding
the COVID-19 outbreak, company management is meeting often to address concerns of our patients, employees, and business, as well as updating and communicating with the Board
regularly. The full Board has oversight and has been engaged concerning the monitoring and identification of risks to the Company, and actions the Company is taking to mitigate risks related to this
outbreak. Board standing committees continue to address risks inherent to their respective areas of oversight. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> MEETINGS OF THE BOARD OF DIRECTORS  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board met five times during the last fiscal year. Each Board member attended 75% or more of the aggregate number of meetings of the
Board and of the committees on which he or she served, held during the portion of the last fiscal year for which he or she was a director or committee member. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
required under applicable Nasdaq listing standards, in fiscal 2019, the Company's independent directors met four times in regularly scheduled executive sessions at which only
independent directors were present. Dr.&nbsp;Selick, the Chairperson of the Board presides over the executive sessions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da70401_information_regarding___da702380"> </A>
<A NAME="toc_da70401_4"> </A>
<BR></FONT><FONT SIZE=2><B>  INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has three committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The
following table provides membership and meeting information for fiscal 2019 for each of the Board committees: </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Audit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Compensation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Nominating and<BR>
Corporate<BR>
Governance </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bryan Giraudo<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chaitan Khosla, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sarah Noonberg, M.D., Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dinesh V. Patel, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harold E. Selick, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Waddill</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lewis T. Williams, M.D., Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Armen Shanafelt, Ph.D.<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total meetings in fiscal 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Committee
Chairperson
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Mr.&nbsp;Giraudo
was appointed to serve as a member and Chairperson of the Nominating and Corporate Governance Committee as of March&nbsp;15, 2019 and
was appointed to serve as member of the Audit Committee as of June&nbsp;7, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Dr.&nbsp;Shanafelt
ceased to be Chairperson of the Nominating and Corporate Governance Committee as of March&nbsp;15, 2019 and ceased to be a director
of the Company, a member of the Audit Committee and a member of the Nominating and Corporate Governance Committee upon the expiration of his term at the conclusion of the 2019 Annual Meeting of
Stockholders as of June&nbsp;7, 2019. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=12,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=412286,FOLIO='10',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_da70401_1_11"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below
is a description of each committee of the Board. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has determined that
each member of each committee meets the applicable Nasdaq rules and regulations regarding "independence" and each member is free of any relationship that would impair his or her individual exercise of
independent judgment with regard to the&nbsp;Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Audit Committee  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee was established by the Board in accordance with Section&nbsp;3(a)(58)(A) of the Securities Exchange Act of 1934,
as amended (the&nbsp;"Exchange Act"), to oversee the Company's corporate accounting and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee
performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent auditors; determines and approves the engagement of the independent
auditors; determines whether to retain or terminate the existing independent auditors or to appoint and engage new independent auditors; reviews and approves the retention of the independent auditors
to perform any proposed permissible non-audit services; monitors the rotation of partners of the independent auditors on the Company's audit engagement team as required by law; reviews and approves or
rejects transactions between the Company and any related persons; confers with management and the independent auditors regarding the effectiveness of internal control over financial reporting;
establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding accounting, internal accounting controls or auditing
matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and meets to review the Company's annual audited financial
statements and quarterly financial statements with management and the independent auditor, including a review of the Company's disclosures under "Management's Discussion and Analysis of Financial
Condition and Results of&nbsp;Operations." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee is composed of three directors: Mr.&nbsp;Waddill, Mr.&nbsp;Giraudo and Dr.&nbsp;Noonberg. The Audit Committee met six times during the fiscal year. The Board
has adopted a written Audit Committee charter that is available to stockholders in the "Corporate Governance" section of the Company's website at www.protagonist-inc.com. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board reviews the Nasdaq listing standards definition of independence for Audit Committee members on an annual basis and has determined that all members of the Audit Committee are
independent (as&nbsp;independence is currently defined in Rule&nbsp;5605(c)(2)(A)(i) and&nbsp;(ii) of the Nasdaq listing standards). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has also determined that Mr.&nbsp;Waddill qualifies as an "audit committee financial expert," as defined in applicable SEC rules. The Board made a qualitative assessment of
Mr.&nbsp;Waddill's level of knowledge and experience based on a number of factors, including his formal education and experience as a chief financial officer for public reporting companies. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Report of the Audit Committee of the Board of Directors  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December&nbsp;31, 2019 with
management of the Company. The Audit
Committee has discussed with PricewaterhouseCoopers&nbsp;LLP, the Company's independent registered public accounting firm for the fiscal year ended December&nbsp;31, 2019, the matters required to
be discussed by Auditing Standard No.&nbsp;1301, </FONT><FONT SIZE=2><I>Communications with Audit Committees,</I></FONT><FONT SIZE=2> as adopted by the Public Company Accounting Oversight Board
("PCAOB"). The Audit Committee has also received the written disclosures and the letter from PricewaterhouseCoopers&nbsp;LLP required by applicable requirements of the PCAOB regarding the
independent accountants' communications with the audit committee concerning independence and has discussed with PricewaterhouseCoopers&nbsp;LLP the accounting firm's independence. Based on the
foregoing, the Audit Committee has recommended to the Board that the audited financial statements be included in the Company's Annual Report on Form&nbsp;10-K for the fiscal year ended
December&nbsp;31,&nbsp;2019. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Mr.&nbsp;William
D. Waddill<BR>
Mr.&nbsp;Bryan Giraudo<BR>
Dr.&nbsp;Sarah Noonberg </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=13,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=788606,FOLIO='11',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_da70401_1_12"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> The material in this report is not "soliciting material," is not deemed "filed" with the Commission and is not to be incorporated by reference in any filing of the Company
under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such&nbsp;filing.  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Compensation Committee  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is composed of three directors: Dr.&nbsp;Selick, Mr.&nbsp;Waddill and Dr.&nbsp;Williams. All members
of the Compensation Committee are independent (as&nbsp;independence is currently defined in Rule&nbsp;5605(d)(2) of the Nasdaq listing standards and regulations of the SEC), and are "non-employee
directors" as defined in Rule&nbsp;16b-3 promulgated under the Exchange Act. The Compensation Committee met three times during the fiscal year. The Board has adopted a written Compensation Committee
charter that is available to stockholders in the "Corporate Governance" section of the Company's website at www.protagonist-inc.com. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee of the Board acts on behalf of the Board to review, adopt and oversee the Company's compensation strategy, policies, plans and programs,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>determining the compensation and other terms of employment of the chief executive officer and the other executive officers
and reviewing and approving corporate performance goals and objectives relevant to such compensation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>reviewing and recommending to the full Board the compensation of the Company's directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>evaluating and administering the equity incentive plans, compensation plans and similar programs advisable for us, as well
as reviewing and recommending to the Board the adoption, modification or termination of the Company's plans and programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>establishing policies with respect to equity compensation arrangements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>administration of the Company's equity compensation plans, pension and profit-sharing plans, deferred compensation plans
and other similar plans and programs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>conducting an annual assessment of the performance of the Compensation Committee and its members, and the adequacy of its
charter. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, once the Company ceases to be an "emerging growth company" as defined in the Jumpstart Our Business Startups Act of 2012, the Compensation Committee will review with
management the Company's Compensation Discussion and Analysis and consider whether to recommend that it be included in proxy statements and other&nbsp;filings. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> Compensation Committee Processes and Procedures  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Typically, the Compensation Committee meets as often as its members deem necessary or appropriate. The agenda for each meeting is
usually developed by the Chairperson of the Compensation Committee, in consultation with the Company's Chief Executive Officer. The Compensation Committee meets regularly in executive session.
However, from time to time, various members of management and other employees as well as outside advisors or consultants may be invited by the Compensation Committee to make presentations, to provide
financial or other background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any
deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The charter of the Compensation Committee grants the Compensation
Committee full access to all books, records, facilities and personnel of the Company. In addition, under the charter, the Compensation Committee has the authority to obtain, at the expense of the
Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors and other external resources that the Compensation Committee considers
necessary or appropriate in the performance of its duties. The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the purpose of
advising the Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion, compensation consultants to assist in its evaluation of executive and
director compensation, including the authority to approve the consultant's reasonable fees and other retention terms. Under the charter, the Compensation Committee may select, or receive advice from,
a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=14,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=616622,FOLIO='12',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_da70401_1_13"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>compensation
consultant, legal counsel or other adviser to the compensation committee, other than in-house legal counsel and certain other types of advisers, only after taking into consideration six
factors, prescribed by the SEC and Nasdaq, that bear upon the adviser's independence; however, there is no requirement that any adviser be&nbsp;independent. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the past fiscal year, after taking into consideration the six factors prescribed by the SEC and Nasdaq described above, the Compensation Committee engaged Radford, an Aon Hewitt
Company, as compensation consultants. Radford was selected because it is a well-known and respected national compensation consulting firm that commonly provides information, recommendations and other
executive compensation advice to compensation committees and management. The Compensation Committee requested that&nbsp;Radford:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>evaluate the efficacy of the Company's existing compensation strategy and practices in supporting and reinforcing the
Company's long-term strategic goals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>assist in refining the Company's compensation strategy and in developing and implementing an executive compensation
program to execute that strategy. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of its engagement, Radford was requested by the Compensation Committee to develop a comparative group of companies and to perform analyses of competitive performance and
compensation levels for that group; as well as conduct market research and analysis on annual and long-term incentive programs, salaries, and equity plans; assist in developing target grant levels,
target bonus levels, and annual salaries for executive officers and other employees; provide the committee with advice and ongoing recommendations regarding material executive compensation decisions;
and review the director compensation program. Radford ultimately developed recommendations that were presented to the Compensation Committee for its consideration. Following an active dialogue with
Radford and resulting modifications, the Compensation Committee approved the modified Radford recommendations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
May&nbsp;25, 2017, the Compensation Committee amended its New&nbsp;Hire and Merit Equity Grant Delegation Policy pursuant to which delegated authority was granted to
Dr.&nbsp;Patel, as the sole member of the Equity Award Committee of the Board, the full authority of the Board, to grant equity-based awards, within Board-approved guidelines, under the Company's
2016 Equity Incentive Plan (the&nbsp;"2016 Plan"). The purpose of this delegation of authority is to enhance the flexibility of option administration within the Company and to facilitate the timely
grants of equity-based awards to service providers of the&nbsp;Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
fiscal 2019, Dr.&nbsp;Patel exercised his authority to grant options to purchase an aggregate of 485,200&nbsp;shares to&nbsp;employees. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee and the Board retain concurrent authority to make equity-based awards to employees and consultants who are eligible recipients under this policy pursuant to
the 2016 Plan. The Compensation Committee receives periodic reports of grants made pursuant to this delegated authority. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically,
the Compensation Committee has made most of the significant adjustments to annual compensation, determined bonus and equity-based awards and established new performance
objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for
new executive hires, as well as high-level strategic issues, such as the efficacy of the Company's compensation strategy, potential modifications to that strategy and new trends, plans or approaches
to compensation, at various meetings throughout the year. Generally, the Compensation Committee's process comprises two related elements: the determination of compensation levels and the establishment
of performance objectives for the current year. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to
the Committee by the Chief Executive Officer. In the case of the Chief Executive Officer, the evaluation of his performance is conducted by the Compensation Committee, which determines any adjustments
to his compensation as well as awards to be granted. For all executives and directors as part of its deliberations, the Compensation Committee may review and consider, as appropriate, materials such
as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical
scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels and
recommendations of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=15,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=738152,FOLIO='13',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_da70401_1_14"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Compensation
Committee's compensation consultant, including analyses of executive and director compensation paid at other companies identified by the&nbsp;consultant. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the members of the Compensation Committee is currently or has been at any time one of the Company's officers or employees. None
of the Company's executive officers currently serves, or has served during the last year, as a member of the board or compensation committee of any entity that has one or more executive officers
serving as a member of the Board or Compensation Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Nominating and Corporate Governance Committee  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nominating and Corporate Governance Committee of the Board is responsible for identifying, reviewing and evaluating candidates to
serve as directors of the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent directors, recommending to the Board for selection candidates for election to the
Board, making recommendations to the Board regarding the membership of the committees of the Board, assessing the performance of management and the Board, and developing a set of corporate governance
principles for the&nbsp;Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominating and Corporate Governance Committee is currently composed of three directors: Mr.&nbsp;Giraudo, Dr.&nbsp;Selick and Dr.&nbsp;Khosla. Mr.&nbsp;Giraudo joined and
became Chairperson of the Nominating and Corporate Governance Committee in March 2019. All members of the Nominating and Corporate Governance Committee are independent (as&nbsp;independence is
currently defined in Rule&nbsp;5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met one time during the fiscal year. The Board has adopted a written
Nominating and Corporate Governance Committee charter that is available to stockholders in the "Corporate Governance" section of the Company's website at www.protagonist-inc.com. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominating and Corporate Governance Committee believes that candidates for director should have certain minimum qualifications, including the ability to read and understand basic
financial statements, being over 21&nbsp;years of age and having the highest personal integrity and ethics. The Nominating and Corporate Governance Committee also intends to consider such factors as
possessing relevant expertise upon which to be able to offer advice and guidance to management, having sufficient time to devote to the affairs of the
Company, demonstrated excellence in his or her field, having the ability to exercise sound business judgment and having the commitment to rigorously represent the long-term interests of the Company's
stockholders. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the
context of the current composition of the Board, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Nominating and Corporate
Governance Committee typically considers diversity (including geographic, gender, racial and ethnic diversity), age, skills and such other factors as it deems appropriate, given the current needs of
the Board and the Company, to maintain a balance of knowledge, experience and&nbsp;capability. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominating and Corporate Governance Committee appreciates the value of thoughtful Board refreshment, and regularly identifies and considers qualities, skills and other director
attributes that would enhance the composition of the Board. In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these
directors' overall service to the Company during their terms, including the number of meetings attended, level of participation, quality of performance and any other relationships and transactions
that might impair the directors' independence. The Committee also takes into account the results of the Board's self-evaluation, conducted annually on a group and individual basis. In the case of new
director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq purposes, which determination is based upon applicable Nasdaq
listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee then uses its network of contacts to compile a list
of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries
into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=16,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=989028,FOLIO='14',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_da70401_1_15"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
Corporate Governance Committee meets to discuss and consider the candidates' qualifications and then selects a nominee for recommendation to the Board by majority&nbsp;vote. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominating and Corporate Governance Committee will consider director candidates recommended by stockholders. The Nominating and Corporate Governance Committee does not intend to
alter the manner in which it evaluates candidates, including the minimum criteria set forth above, based on whether or not the candidate was recommended by a stockholder. Stockholders who wish to
recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation to the
Nominating and Corporate Governance Committee at the following address: 7707&nbsp;Gateway Blvd., Suite&nbsp;140, Newark, California 94560. Submissions must include the full name of the proposed
nominee, a description of the proposed nominee's business experience for at least the previous five years, complete biographical information, a description of the proposed nominee's qualifications as
a director and a representation that the nominating stockholder is a beneficial or record holder of the Company's stock and has been a holder for at least one year. Any such submission must be
accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if&nbsp;elected. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> STOCKHOLDER COMMUNICATIONS WITH THE BOARD OF DIRECTORS  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically, the Company has not provided a formal process related to stockholder communications with the Board. Nevertheless, every
effort has been made to ensure that the views of stockholders are heard by the Board or individual directors, as applicable, and that appropriate responses are provided to stockholders in a timely
manner. The Company believes its responsiveness to stockholder communications to the Board has been&nbsp;excellent. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> CODE OF ETHICS  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has adopted the Protagonist Therapeutics,&nbsp;Inc. Code of Business Conduct and Ethics that applies to all officers,
directors and employees. The Code of Business Conduct and Ethics is available in the "Corporate Governance" section of the Company's website at www.protagonist-inc.com. If the Company makes any
substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code to any executive officer or director, the Company will promptly disclose the nature
of the amendment or waiver on its&nbsp;website. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> CORPORATE GOVERNANCE GUIDELINES  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July&nbsp;2016, the Board documented the governance practices followed by the Company by adopting Corporate Governance Guidelines
to assure that the Board will have the necessary authority and practices in place to review and evaluate the Company's business operations as needed and to make decisions that are independent of the
Company's management. The guidelines are also intended to align the interests of directors and management with those of the Company's stockholders. The Corporate Governance Guidelines set forth the
practices the Board intends to follow with respect to board composition and selection, including diversity, board meetings and involvement of senior management, Chief Executive Officer performance
evaluation and succession planning, and board committees and compensation. The Corporate Governance Guidelines, as well as the charters for each committee of the Board, may be viewed on the "Corporate
Governance" section of the Company's website at www.protagonist-inc.com. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=17,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=913622,FOLIO='15',FILE='DISK135:[20ZAD1.20ZAD70401]DA70401A.;26',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dc70401_1_16"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc70401_proposal_2_ratification_of_sel__pro03396"> </A>
<A NAME="toc_dc70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>PROPOSAL 2</B></FONT><FONT SIZE=2><B><BR>  <BR>    </B></FONT><FONT SIZE=2><B>RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee of the Board has selected Ernst&nbsp;&amp; Young&nbsp;LLP as the Company's independent registered public accounting firm for the fiscal
year ending December&nbsp;31, 2020 and has further directed that management submit the selection of its independent registered public accounting firm for ratification by the stockholders at the
Annual Meeting. Representatives of Ernst&nbsp;&amp; Young&nbsp;LLP are expected to be present at the Annual Meeting. They will have an opportunity to make a statement if they so desire and will be
available to respond to appropriate questions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst
&amp; Young&nbsp;LLP has served as our independent registered public accounting firm since March&nbsp;31, 2020. Prior to such time, PricewaterhouseCoopers&nbsp;LLP served as our
independent registered public accounting firm. See "Change in Auditors for the Fiscal Year Ending December&nbsp;31, 2020" below. The Company does not expect that a representative of
PricewaterhouseCoopers&nbsp;LLP will be present at the Annual&nbsp;Meeting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
the Company's Amended and Restated Bylaws nor other governing documents or law require stockholder ratification of the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as the
Company's independent registered public accounting firm. However, the Audit Committee is submitting the selection of Ernst&nbsp;&amp; Young&nbsp;LLP to the stockholders for ratification as a matter of
good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether or not to retain that firm. Even if the selection is
ratified, the Audit Committee in its discretion may direct the appointment of different independent auditors at any time during the year if they determine that such a change would be in the best
interests of the Company and its stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
affirmative vote of the holders of a majority of the shares present online during the virtual meeting or represented by proxy and entitled to vote on the matter at the Annual Meeting
will be required to ratify the selection of Ernst&nbsp;&amp; Young&nbsp;LLP. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>CHANGE IN AUDITORS FOR THE FISCAL YEAR ENDING DECEMBER&nbsp;31, 2020.</B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;13, 2020, the Audit Committee approved the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as the Company's independent
registered public accounting firm to audit the Company's financial statements for the fiscal year ending December&nbsp;31, 2020, in place of PricewaterhouseCoopers&nbsp;LLP. The decision to change
our accounting firm was authorized by the Audit Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PricewaterhouseCoopers&nbsp;LLP's
report on the financial statements for the past two years contained no adverse opinion or disclaimer of opinion and was not qualified as to audit
scope or accounting principles. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the Company's audits for the fiscal years ended December&nbsp;31, 2019 and 2018, and in the subsequent period before PricewaterhouseCoopers&nbsp;LLP's dismissal on
March&nbsp;13, 2020, there were no disagreements with PricewaterhouseCoopers&nbsp;LLP on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or
procedure, that would have caused PricewaterhouseCoopers&nbsp;LLP to report the disagreement if it had not been resolved to the satisfaction of PricewaterhouseCoopers&nbsp;LLP. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PricewaterhouseCoopers&nbsp;LLP's
reports on the financial statements for the past two years did not contain an adverse opinion or disclaimer of an opinion nor were they qualified or
modified as to uncertainty, audit scope or accounting principles. PricewaterhouseCoopers&nbsp;LLP's letter to the SEC stating its agreement with the statements in this paragraph was filed as an
exhibit to the Company's Current Report on Form&nbsp;8-K dated March&nbsp;18,&nbsp;2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the fiscal years ended December&nbsp;31, 2019 and 2018 and any subsequent interim period before the Company's engagement of Ernst&nbsp;&amp; Young&nbsp;LLP, the Company did not
consult with Ernst&nbsp;&amp; Young&nbsp;LLP regarding the application of accounting principles to a specified transaction, or the type of audit opinion that might be rendered on the Company's
financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=137937,FOLIO='16',FILE='DISK135:[20ZAD1.20ZAD70401]DC70401A.;41',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_dc70401_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>PRINCIPAL ACCOUNTANT FEES AND SERVICES</B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table represents aggregate fees billed to the Company for the fiscal years ended December&nbsp;31, 2019 and December&nbsp;31, 2018 by
PricewaterhouseCoopers&nbsp;LLP, the Company's previous principal accountant and independent registered accounting firm. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fiscal Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,185,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>785,570</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,091</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,200,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>795,661</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
<TD COLSPAN=2 ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:times;">&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>"Audit
Fees" consist of fees billed for professional services rendered for the audit of the Company's consolidated financial statements included in the
Company's Annual Report on Form&nbsp;10-K and&nbsp;for the review of the financial statements included in the Company's Quarterly Reports on Form&nbsp;10-Q, as well as services as are normally
provided by the Company's independent registered public accounting firm, including statutory audits and services rendered in connection with statutory and regulatory filings or engagements for those
fiscal years. The Audit Fees incurred in 2019 also include fees of $270,000 related to services performed in connection with the Company's at-the-market offerings and a shelf registration statement on
Form&nbsp;S-3, including comfort letters, consents and review of documents filed with the SEC. The Audit Fees incurred in 2018 also include fees of $80,000 related to services performed in
connection with the Company's private placement and at-the-market offerings, including comfort letters and a shelf registration statement on Form&nbsp;S-3 and&nbsp;a subsequent follow-on public
offering, including comfort letters, consents and review of documents filed with the SEC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>"Audit-Related
Fees" consist of fees billed for related services by the principal accountant that are reasonably related to the performance of the audit or
review of the Company's financial statements and are not reported under the Audit Fees category.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>"Tax
Fees" in 2019 and 2018 consist primarily of fees billed for professional services rendered in connection with indirect tax compliance in foreign tax
jurisdictions (Australia). As the Company's subsidiary is incorporated in Australia, a substantial portion of the Tax Fees are denominated in Australian Dollars (AUD) and have been translated into
U.S.&nbsp;Dollars (USD) using the average exchange rate for each applicable period listed in the table below. </FONT></DD></DL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:20%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>AUD: USD </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>AUD </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>USD </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019 Average</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.00: 0.69696</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,340</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018 Average</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.00: 0.79326</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,091</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>"All
Other Fees" consist of fees related to products and services provided by the principal accountant, other than the services reported above. </FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All fees described above were pre-approved by the Audit Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the audit of the 2019 financial statements, the Company entered into an engagement agreement with PricewaterhouseCoopers&nbsp;LLP that set forth the terms by which
PricewaterhouseCoopers&nbsp;LLP would perform audit services for the Company. That agreement was subject to alternative dispute resolution procedures and an exclusion of punitive damages. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the fiscal year ended December&nbsp;31, 2019, none of the total hours expended on the Company's financial audit by PricewaterhouseCoopers&nbsp;LLP were provided by persons
other than PricewaterhouseCoopers&nbsp;LLP's full-time permanent employees. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>PRE-APPROVAL POLICIES AND PROCEDURES</B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services rendered by the Company's independent registered
public
accounting firm, Ernst&nbsp;&amp; Young&nbsp;LLP. The policy generally pre-approves specified services in the defined categories of audit services, audit-related services and tax services up to
specified amounts. Pre-approval may also be given as part of the Audit Committee's approval of the scope of the engagement of the independent auditor or on an individual, explicit, case-by-case basis
before the independent auditor is engaged to provide each service. The pre-approval of services may be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=19,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=403100,FOLIO='17',FILE='DISK135:[20ZAD1.20ZAD70401]DC70401A.;41',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_dc70401_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>delegated
to one or more of the Audit Committee's members, but the decision must be reported to the full Audit Committee at its next scheduled meeting. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee has determined that the rendering of services other than audit services by Ernst&nbsp;&amp; Young&nbsp;LLP is compatible with maintaining the principal accountant's
independence. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc70401_the_board_of_directors_recomme__the02472"> </A>
<A NAME="toc_dc70401_2"> </A>
<BR></FONT><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS<BR>  A VOTE IN FAVOR OF PROPOSAL 2.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=20,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=590445,FOLIO='18',FILE='DISK135:[20ZAD1.20ZAD70401]DC70401A.;41',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_de70401_1_19"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de70401_executive_officers"> </A>
<A NAME="toc_de70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information with respect to the Company's current executive officers as of
March&nbsp;13,&nbsp;2020. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dinesh V. Patel, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Y. Liu, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer and Head of Research and Development</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald A. Kalkofen</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Samuel Saks, M.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Suneel Gupta, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Development Officer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Dinesh V. Patel, Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biographical information for Dr.&nbsp;Patel is included above with the director biographies under the caption "Nominees for Election
to Class&nbsp;I for a Three-Year Term Expiring at the 2023 Annual Meeting." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> David Y. Liu, Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Liu has served as the Company's Chief Scientific Officer since May&nbsp;2013 and has served as Chief Scientific Officer
and Head of Research and Development since February&nbsp;2016. Prior to Protagonist, Dr.&nbsp;Liu was the Chief Operating Officer and a cofounder of Trenovus,&nbsp;Inc., from 2010 to 2012. Prior
to Trenovus, Dr.&nbsp;Liu was Vice President of Research at FibroGen&nbsp;Inc., from 2002 to 2010. Prior to FibroGen, Dr.&nbsp;Liu served as Director of Inflammation Research at
Scios,&nbsp;Inc., now part of Johnson&nbsp;&amp; Johnson, from 1992 to 2002. Dr.&nbsp;Liu held a position as an academic researcher at Brigham and Women's Hospital, Harvard Medical School and was
Instructor and Assistant Professor in the Department of Medicine, Harvard Medical School, from 1976 to 1986. Dr.&nbsp;Liu received his Ph.D. in microbiology and immunology from Michigan State
University, and his B.S. in Chemistry from The University of&nbsp;Chicago. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Donald A. Kalkofen  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Kalkofen has served as the Company's Chief Financial Officer since May 2019, after serving in a consulting capacity as the
Company's Senior Advisor, Finance since February&nbsp;11, 2019 until his appointment as Chief Financial Officer. He previously served in a consulting capacity as Interim Controller of the Company
from May 2018 to June 2018. He served as Interim Chief Financial Officer of App Annie,&nbsp;Inc., a global SaaS company, from June 2018 to January 2019. From November 2017 until April 2018.
Mr.&nbsp;Kalkofen served as a Financial Consultant at Depomed,&nbsp;Inc. (now Assertio Therapeutics,&nbsp;Inc.), a specialty pharmaceutical company. He also served as a Chief Financial Officer
consulting partner at Hardesty,&nbsp;LLC, a financial executive consulting firm, from July 2016 to November 2018. Mr.&nbsp;Kalkofen served at Align Technology,&nbsp;Inc., a global medical device
company, as Interim Assistant Controller from May 2016 to October 2017. He served as a Financial Consultant at Marketo,&nbsp;Inc., a marketing software company from March 2016 to May 2016.
Mr.&nbsp;Kalkofen served as President and Vice President of Finance, Consultant at Simplifier Corporation, a SaaS expense reporting solutions company, which he co-founded, from October 2014 to May
2016. He also held positions with Symantec Corporation, a cybersecurity software company, from 2012 through October 2014. Mr.&nbsp;Kalkofen's experience also includes serving as CFO of Pinnacle Bank
in Oregon from 2002 to 2007 and CFO of Westcoast Bancorp from 1992 to 2000. He began his career at PricewaterhouseCoopers&nbsp;LLP as part of the firm's audit practice group. Mr.&nbsp;Kalkofen
holds a B.A. in Accounting from Washington State University, is an active Certified Public Accountant and Certified Global Management Accountant. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Samuel Saks, M.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Saks has served as the Company's Chief Medical Officer since May&nbsp;2019, and served as the Company's Chief Development
Officer from May&nbsp;2018 to May&nbsp;2019. Prior to joining Protagonist, he served as Chief Development Officer and board member at Auspex Pharmaceuticals, a biopharmaceutical company, from
December&nbsp;2010 until the time of its acquisition by Teva Pharmaceuticals in May&nbsp;2015. Before his tenure at </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=21,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=947404,FOLIO='19',FILE='DISK135:[20ZAD1.20ZAD70401]DE70401A.;27',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_de70401_1_20"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Auspex,
Dr.&nbsp;Saks was a co-founder of Jazz Pharmaceuticals where he also previously served as Chief Executive Officer of Jazz from March&nbsp;2003 to March&nbsp;2009. Earlier in his career,
he held positions as company group chairman of ALZA Corporation and as a member of the Johnson&nbsp;&amp; Johnson Pharmaceutical Operating Committee. Dr.&nbsp;Saks has also held leadership and
management positions at Schering-Plough, XOMA Corporation and Genentech. He previously served as a director of PDL BioPharma, a public company, until August&nbsp;2019, as a director of Tonix
Pharmaceutical Holding Company, a public company, from May 2012 until August&nbsp;2018 and as a director of Depomed&nbsp;Inc. (now Assertio Therapeutics), a public company, from October 2012 until
March 2017. Dr.&nbsp;Saks also serves as a director of two privately held companies. Dr.&nbsp;Saks received a B.S. in Biology and his M.D. from the University of&nbsp;Illinois. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Suneel Gupta, Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Gupta has served as the Company's Chief Development Officer since May&nbsp;2019, and served as the Company's Executive
Vice President of Clinical Pharmacology and Clinical Operations from January&nbsp;2019 to May&nbsp;2019. Prior to joining Protagonist, he was Chief Scientific Officer of Impax Pharmaceuticals from
2008 to January&nbsp;2019. Prior to Impax, Dr.&nbsp;Gupta was Senior Vice President and Distinguished Research Fellow at Johnson&nbsp;&amp; Johnson, where he led the early development from 2002
through 2008. Prior to Johnson&nbsp;&amp; Johnson, he held positions at ALZA Corporation from 1989 through 2001, where he had increasing levels of responsibility until ultimately being promoted to Vice
President of Clinical Pharmacology&nbsp;&amp; Product Discovery. Dr.&nbsp;Gupta serves on the scientific advisory boards of several pharmaceutical companies. He received his Ph.D. in Pharmacokinetics
from the University of Manchester, UK in 1987 and did a postdoctoral fellowship in Clinical Pharmacology at the University of California, San&nbsp;Francisco. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=22,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=295956,FOLIO='20',FILE='DISK135:[20ZAD1.20ZAD70401]DE70401A.;27',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_de70401_1_21"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de70401_security_ownership_of_certain___sec02525"> </A>
<A NAME="toc_de70401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF<BR>  CERTAIN BENEFICIAL OWNERS AND MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding the ownership of the Company's common stock as of March&nbsp;13, 2020
by: (i)&nbsp;each director and nominee for director; (ii)&nbsp;each of the named executive officers named in the Summary Compensation Table; (iii)&nbsp;all executive officers and directors of
the Company as a group; and (iv)&nbsp;all those known by the Company to be beneficial owners of more than five percent of its common&nbsp;stock. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Beneficial Ownership<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:60pt;"><FONT SIZE=1><B>Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,60pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent of Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>5% Stockholders:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BlackRock,&nbsp;Inc.<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,561,957</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Biotechnology Value Fund,&nbsp;LP and its affiliated entities<SUP>(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,332,630</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Farallon Partners,&nbsp;LLC<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FMR&nbsp;LLC<SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,080,967</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Johnson&nbsp;&amp; Johnson Development Corporation<SUP>(6)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,449,183</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lilly Ventures Fund 1,&nbsp;LLC<SUP>(7)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,099,482</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RTW Investments,&nbsp;LP<SUP>(8)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,459,988</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Executive Officers and Directors:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dinesh V. Patel, Ph.D.<SUP>(9)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,114,809</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Suneel Gupta, Ph.D.<SUP>(10)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64,447</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Y. Liu, Ph.D.<SUP>(11)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>284,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harold E. Selick, Ph.D.<SUP>(12)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bryan Giraudo<SUP>(13)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chaitan Khosla, Ph.D.<SUP>(14)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>86,638</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sarah Noonberg, M.D., Ph.D.<SUP>(15)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Waddill<SUP>(16)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lewis T. Williams, M.D., Ph.D.<SUP>(17)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>All executive officers and directors as a group (11&nbsp;persons)<SUP>(18)</SUP></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,879,540</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Represents
beneficial ownership of less than one percent of the outstanding common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>This
table is based upon information supplied by officers, directors and principal stockholders and Schedules&nbsp;13D and&nbsp;13G filed with the SEC.
Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, the Company believes that each of the stockholders named in this table has sole
voting and investment power with respect to the shares indicated as beneficially owned. Applicable percentages are based on 27,424,705&nbsp;shares outstanding on March&nbsp;13, 2020 adjusted as
required by rules promulgated by the SEC. Pursuant to the rules of the SEC, the number of shares of common stock deemed outstanding includes shares issuable upon settlement of restricted stock units
("RSUs") held by the respective person or group that will vest within 60&nbsp;days of March&nbsp;13, 2020 and pursuant to options held by the respective person or group that are currently
exercisable or may be exercised within 60&nbsp;days of March&nbsp;13, 2020. Unless otherwise indicated, the address for each of beneficial owner is c/o Protagonist Therapeutics,&nbsp;Inc.,
7707&nbsp;Gateway Blvd., Suite&nbsp;140, Newark, California 94560.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>This
information is based solely upon a Schedule&nbsp;13G filed with the SEC on February&nbsp;7, 2020 by BlackRock,&nbsp;Inc. ("BlackRock"). The
Schedule&nbsp;13G reports that BlackRock has sole voting power with respect to 1,544,646&nbsp;shares and sole dispositive power with respect to 1,561,957&nbsp;shares. BlackRock is located at
55&nbsp;East 52nd&nbsp;Street, New&nbsp;York, NY 10055.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>This
information is based solely upon Amendment No.&nbsp;3 to Schedule&nbsp;13G/A filed with the SEC by Biotechnology Value Fund,&nbsp;L.P. ("BVF") on
February&nbsp;14, 2020. Consists of 1,117,193&nbsp;shares held by BVF, 896,161&nbsp;shares held by Biotechnology Value Fund II,&nbsp;L.P. ("BVF2"), and 165,691&nbsp;shares held by
Biotechnology Value Trading Fund OS&nbsp;LP ("Trading Fund OS"). BVF I&nbsp;GP&nbsp;LLC ("BVF&nbsp;GP"), as the general partner of BVF, may be deemed to beneficially own the
1,117,193&nbsp;shares beneficially owned by BVF. BVF II&nbsp;GP&nbsp;LLC ("BVF2&nbsp;GP"), as the general partner of BVF2, may be deemed to beneficially own the 896,161&nbsp;shares
beneficially owned by BVF2. BVF Partners OS&nbsp;Ltd. ("Partners OS"), as the general partner of Trading Fund OS, may be deemed to beneficially own the 165,691&nbsp;shares beneficially owned by
Trading Fund OS. BVF&nbsp;GP Holdings&nbsp;LLC ("BVF&nbsp;GPH"), as the sole member of each of BVF&nbsp;GP and BVF2&nbsp;GP, may be deemed to beneficially own the 2,013,354&nbsp;shares
beneficially owned in the aggregate by BVF and BVF2. BVF Partners&nbsp;L.P. ("Partners"), as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be
deemed to beneficially own the 2,332,630&nbsp;shares beneficially owned in the aggregate by BVF, BVF2, and Trading Fund OS, including 153,585&nbsp;shares held in the Partners managed accounts,
which includes 64,870&nbsp;shares underlying certain Class&nbsp;A Warrants and 64,870&nbsp;shares underlying certain Class&nbsp;B Warrants. BVF&nbsp;Inc., as the general partner of Partners,
may be deemed to beneficially own the 2,332,630&nbsp;shares beneficially owned by Partners. Mark N. Lampert, as a director and officer of BVF&nbsp;Inc., may be deemed to </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=23,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=379486,FOLIO='21',FILE='DISK135:[20ZAD1.20ZAD70401]DE70401A.;27',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_de70401_1_22"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>beneficially
own the 2,332,630&nbsp;shares beneficially owned by BVF&nbsp;Inc. The address for BVF, BVF&nbsp;GP, BVF2, BVF2&nbsp;GP, BVF&nbsp;GPH, Partners, BVF&nbsp;Inc. and Mark N.
Lampert is 44&nbsp;Montgomery Street, 40th&nbsp;Floor, San Francisco, CA 94104. The address of Trading Fund OS and Partners OS is PO Box&nbsp;309 Ugland House, Grand Cayman, KY1-1104, Cayman
Islands.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>This
information is based solely upon Amendment No.&nbsp;2 to Schedule&nbsp;13G/A jointly filed with the SEC on February&nbsp;7, 2020 by the following
entities and persons: (i)&nbsp;Farallon Partners, L.L.C. ("Farallon General Partner"); (ii)&nbsp;Farallon Institutional (GP) V, L.L.C. ("FCIP V General Partner"); and (iii)&nbsp;Philip D.
Dreyfuss, Michael B. Fisch, Richard B. Fried, David T. Kim, Monica R. Landry, Michael G. Linn, Rajiv A. Patel, Thomas G. Roberts, Jr., William Seybold, Andrew J. M. Spokes, John R. Warren and Mark C.
Wehrly (collectively, the "Farallon Individual Reporting Persons"). Consists of 527,823&nbsp;shares held by Farallon Capital Partners,&nbsp;L.P. ("FCP"), 556,354&nbsp;shares held by Farallon
Capital Institutional Partners,&nbsp;L.P. ("FCIP"), 99,858&nbsp;shares held by Farallon Capital Institutional Partners II,&nbsp;L.P. ("FCIP II"), 64,290&nbsp;shares held by Farallon Capital
Institutional Partners III,&nbsp;L.P. ("FCIP III"), 85,593&nbsp;shares held by Four Crossings Institutional Partners V,&nbsp;L.P. ("FCIP V"), 1,419,322&nbsp;shares held by Farallon Capital
Offshore Investors II,&nbsp;L.P. ("FCOI II"), and 28,531&nbsp;shares held by Farallon Capital (AM) Investors,&nbsp;L.P. ("FCAMI"), (collectively FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II,
and FCAMI are the "Farallon Funds"). Farallon General Partner, as the (i)&nbsp;general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI, and (ii)&nbsp;the sole member of the FCIP
V General Partner, is deemed to be the beneficial owner of 2,781,771&nbsp;shares, including 1,319,271&nbsp;shares for which Warrants are currently exercisable. The Farallon Individual Reporting
Persons, each of whom is a managing member of the Farallon General Partner, a manager or senior manager, as the case may be, of the FCIP V General Partner, are each deemed to beneficially own
2,853,098&nbsp;shares including 1,353,098&nbsp;shares for which Warrants currently are exercisable. The address of the principal business office of the beneficial owners is c/o Farallon Capital
Management, L.L.C., One Maritime Plaza, Suite&nbsp;2100, San Francisco, CA 94111.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>This
information is based solely upon Amendment No.&nbsp;4 to&nbsp;a Schedule&nbsp;13G/A filed jointly with the SEC by FMR&nbsp;LLC and Abigail P.
Johnson on February&nbsp;7, 2020. The filing reports that FMR&nbsp;LLC held sole voting power over 564,624&nbsp;shares and no shared voting power and sole dispositive power of
4,080,967&nbsp;shares and no shared dispositive power. Abigail P. Johnson is a director, the vice chairman, the chief executive officer and the president of FMR&nbsp;LLC and has sole dispositive
power over 4,080,967&nbsp;shares. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series&nbsp;B voting common shares of
FMR&nbsp;LLC, representing 49% of the voting power of FMR&nbsp;LLC. The Johnson family group and all other Series&nbsp;B stockholders have entered into a stockholders' voting agreement under
which all Series&nbsp;B voting common shares will be voted in accordance with the majority vote of Series&nbsp;B voting common shares. Accordingly, through their ownership of voting common shares
and the execution of the stockholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, as amended (the&nbsp;"Investment Company Act"), to
form&nbsp;a controlling group with respect to FMR&nbsp;LLC. Neither FMR&nbsp;LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the
various investment companies registered under the Investment Company Act (the&nbsp;"Fidelity Funds") advised by Fidelity Management&nbsp;&amp; Research Company ("FMR&nbsp;Co."), a wholly owned
subsidiary of FMR&nbsp;LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR&nbsp;Co. carries out the voting of the shares under written guidelines established by the Fidelity
Funds' Boards of Trustees. The address for FMR&nbsp;LLC is 245&nbsp;Summer Street, Boston, MA 02210.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>This
information is based in part upon a Schedule&nbsp;13G filed jointly with the SEC by Johnson&nbsp;&amp; Johnson ("J&amp;J"), and Johnson&nbsp;&amp; Johnson
Innovation-JJDC,&nbsp;Inc. ("JJDC") on August&nbsp;19, 2016. JJDC is a wholly-owned subsidiary of J&amp;J. The securities held by J&amp;J and JJDC are directly beneficially owned by JJDC. J&amp;J may be
deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The board of directors of JJDC, which consists of Paulus Stoffels and Steven Rosenberg, has shared
investment and voting control with respect to the shares held by JJDC and has delegated responsibility therefor to the management of JJDC to take such actions on behalf of JJDC. As such, no individual
member of the JJDC board of directors is deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by JJDC. No individual representative of JJDC shall be deemed
(i)&nbsp;a beneficial owner of, or (ii)&nbsp;to have a reportable pecuniary interest in, the shares held by JJDC. The address of JJDC is One Johnson&nbsp;&amp; Johnson Plaza, New&nbsp;Brunswick,
NJ 08933.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>LV
Management Group,&nbsp;LLC ("LVMG") is the management company for Lilly Ventures Fund I,&nbsp;LLC ("LVFI") and has dispositive power over the shares
held by LVFI. As such, LVMG may be deemed to indirectly beneficially own the shares held by LVFI. LVMG's voting and dispositive decisions with respect to the shares held by LVFI are made by LVMG's
management committee, which consists of Ed Torres, Steve Hall and Armen Shanafelt (collectively, the "Management Committee Members"). The mailing addresses of the beneficial owners is 115&nbsp;West
Washington Street, Suite&nbsp;1680 South, Indianapolis, IN 46204.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>This
information is based solely upon Amendment No.&nbsp;1 to Schedule&nbsp;13G/A jointly filed with the SEC on February&nbsp;14, 2020 by RTW
Investments&nbsp;LP, RTW Master Fund,&nbsp;Ltd. and Roderick Wong. RTW Investments,&nbsp;LP is the investment manager of RTW Master Fund,&nbsp;Ltd. and one or more private funds, and shares
voting and dispositive power over such shares. RTW Investments,&nbsp;LP and Roderick Wong report that they have shared voting and dispositive power with respect to 2,459,988&nbsp;shares. RTW
Master Fund,&nbsp;Ltd reports that it has shared voting and dispositive power with respect to 1,792,314&nbsp;shares. Roderick Wong is the Managing Partner of RTW Investments&nbsp;LP, RTW. The
address of RTW Investments,&nbsp;LP and Roderick Wong is 412&nbsp;West 15th&nbsp;Street, 9th&nbsp;Floor, New&nbsp;York, NY 10011. The address of RTW Master Fund,&nbsp;Ltd. is
190&nbsp;Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
718,882&nbsp;shares issuable pursuant to stock options exercisable within 60&nbsp;days of March&nbsp;13, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
13,125&nbsp;shares issuable pursuant to stock options exercisable within 60&nbsp;days of March&nbsp;13, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
248,386&nbsp;shares issuable pursuant to stock options exercisable within 60&nbsp;days of March&nbsp;13, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
85,710&nbsp;shares issuable pursuant to stock options exercisable within 60&nbsp;days of March&nbsp;13, 2020. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=24,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=403913,FOLIO='22',FILE='DISK135:[20ZAD1.20ZAD70401]DE70401A.;27',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_de70401_1_23"> </A>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(13)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
18,000 shares held indirectly by the Bryan and Courtney Giraudo Trust and 27,333&nbsp;shares issuable pursuant to stock options exercisable
within 60&nbsp;days of March&nbsp;13, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(14)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
86,638&nbsp;shares issuable pursuant to stock options exercisable within 60&nbsp;days of March&nbsp;13, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(15)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Consists
of 31,333&nbsp;shares issuable pursuant to stock options exercisable within 60&nbsp;days of March&nbsp;13, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(16)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Consists
of 60,975&nbsp;shares issuable pursuant to stock options exercisable within 60&nbsp;days of March&nbsp;13, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(17)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Consists
of 35,333&nbsp;shares issuable pursuant to stock options exercisable within 60&nbsp;days of March&nbsp;13, 2020.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(18)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
1,359,130&nbsp;shares that certain executive officers and directors of the Company have the right to acquire within 60&nbsp;days of
March&nbsp;13, 2020 pursuant to the exercise of outstanding options. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><A
NAME="de70401_delinquent_section_16(a)_reports"> </A>
<A NAME="toc_de70401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DELINQUENT SECTION&nbsp;16(A) REPORTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires the Company's directors and executive officers, and persons who own more than ten
percent of a registered class of the Company's equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of
the Company. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish the Company with copies of all Section&nbsp;16(a) forms they&nbsp;file. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
solely on a review of the copies of reports furnished to us and written representations that no other reports were required, during the fiscal year ended December&nbsp;31, 2019,
all Section&nbsp;16(a) filing requirements applicable to the Company's officers, directors and greater than ten percent beneficial owners were complied with, other than one late Form&nbsp;4 filed
by Dr.&nbsp;Khosla to report a grant of an option to purchase Common Stock on August&nbsp;15, 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de70401_executive_compensation"> </A>
<A NAME="toc_de70401_4"> </A>
<BR></FONT><FONT SIZE=2><B>EXECUTIVE COMPENSATION</B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation awarded to or earned by the executive officers listed below during
the years ended December&nbsp;31, 2019 and December&nbsp;31, 2018. As an emerging growth company, the Company complies with the executive compensation disclosure rules applicable to "smaller
reporting companies," as such term is defined in the rules promulgated under the Securities Act of 1933, as amended (the&nbsp;"Securities Act"), which require compensation disclosure for the
principal executive officer and the two most highly compensated executive officers other than the principal executive officer at December&nbsp;31, 2019. These three officers are referred to as the
named executive officers (the&nbsp;"Named Executive Officers"). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de70401_summary_compensation_table_for_fiscal_2019"> </A>
<A NAME="toc_de70401_5"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY COMPENSATION TABLE FOR FISCAL 2019    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:102pt;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,102pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($)<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($)<SUP>(2)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)<SUP>(2)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<BR>
($)<SUP>(3)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)<SUP>(4)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Dinesh&nbsp;V.&nbsp;Patel,&nbsp;Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>545,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>230,575</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>814,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>354,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,164</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,948,344</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>520,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,127,739</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,841,928</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>221,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,844</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,721,511</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Y. Liu, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
428,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
120,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
424,881</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
218,509</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
7,458</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,199,598</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief&nbsp;Scientific&nbsp;Officer and</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>410,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>382,389</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>677,008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,458</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,618,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Head of Research and</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Development</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Suneel&nbsp;Gupta,&nbsp;Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
377,467</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
60,150</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
693,789</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
196,767</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
3,564</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,331,737</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief&nbsp;Development&nbsp;Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
amounts in the "Salary" column reflect each Named Executive Officer's base salary plus any additional amounts paid for unused accrued vacation or sick
time.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
amounts in the "Stock Awards" and "Option Awards" columns reflect the aggregate grant date fair value of RSUs, and stock options, as applicable, granted
during the calendar year and computed in accordance with the provisions of Accounting Standards Codification (ASC) 718, Compensation&nbsp;&#151;&nbsp;Stock Compensation. The
valuation methodology of these awards is described in the notes </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=25,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=420349,FOLIO='23',FILE='DISK135:[20ZAD1.20ZAD70401]DE70401A.;27',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_de70401_1_24"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>to
the Company's financial statements included in its Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019. These amounts do not reflect the actual economic value that will be
realized by the Named Executive Officer upon the vesting of the RSUs and stock options, the exercise of the stock options, or the sale of the common stock underlying such awards. As required by SEC
rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions. With respect to option awards only, the Named Executive Officers will only realize
compensation to the extent the trading price of the common stock is greater than the exercise price of such stock options.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
amounts in the "Non-Equity Incentive Plan Compensation" column for 2019 reflect cash bonuses earned for the 2019 fiscal year, which were paid in 2020,
based on the achievement of certain predetermined corporate objectives specified by the Board, including operating targets and research and development outcomes. In February&nbsp;2020, the
Compensation Committee determined that the Company met 130% of its 2019 corporate objectives and approved the amount of each Named Executive Officer's bonus. The amount of the bonus that each Named
Executive Officer earned for the fiscal year ended on December&nbsp;31, 2019 is listed in the table below. </FONT></DD></DL>
 </DIV>
<DIV style="padding:0pt;position:relative;width:80%;margin-left:20%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 Base<BR>
Salary ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
Bonus </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount of Bonus<BR>
Earned ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dinesh V. Patel, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>545,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>354,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Y. Liu, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>428,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>218,509</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Suneel Gupta, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>377,467</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>196,767</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Amounts
noted for 2019 reflect cash bonuses earned for the 2019 fiscal year, which were paid in 2020, based on the achievement of certain predetermined corporate objectives, as specified by the Board,
including operating targets and research and development outcomes.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
amounts noted for 2019 include $3,564 in group term life insurance for Dr.&nbsp;Patel, $6,858 in group term life insurance for Dr.&nbsp;Liu and
$3,564 in group term life insurance for Dr.&nbsp;Gupta. The amounts noted for 2019 also include $600 in sick leave bonus paid to each of Dr.&nbsp;Patel and Dr.&nbsp;Liu pursuant to companywide
policy. The amounts noted for 2018 include $3,564 in group term life insurance for Dr.&nbsp;Patel and $6,858 in group term life insurance for Dr.&nbsp;Liu. The amounts noted for 2018 also include
$6,680 related to gifting of shares purchased through the 2016 Employee Stock Purchase Plan for Dr.&nbsp;Patel, $600 in sick leave bonus paid to each of Dr.&nbsp;Patel and Dr.&nbsp;Liu pursuant
to companywide policy, and $98,105 in cash compensation for consulting services paid to Dr.&nbsp;Gupta prior to his employment with the Company. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de70401_narrative_to_summary_compensation_table"> </A>
<A NAME="toc_de70401_6"> </A>
<BR></FONT><FONT SIZE=2><B>  NARRATIVE TO SUMMARY COMPENSATION TABLE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> EXECUTIVE EMPLOYMENT ARRANGEMENTS WITH NAMED EXECUTIVE OFFICERS  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Employment Agreement with Dinesh V. Patel, Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December&nbsp;2008, the Company entered into an employment agreement with Dinesh V. Patel. Ph.D., the Company's President and
Chief Executive Officer, as amended in December&nbsp;2015, pursuant to which he commenced employment. For 2020, Dr.&nbsp;Patel will receive an annual base salary of $565,000, with an annual target
bonus of 55% of that base salary. The amount, if any, of such bonus with respect to any calendar year is based on the achievement of predetermined corporate and personal objectives as determined by
the Board in its&nbsp;discretion. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Offer Letter Agreement with David Y. Liu, Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In May&nbsp;2013, the Company entered into an offer letter agreement with David Liu, Ph.D., the Company's Chief Scientific Officer,
pursuant to which he commenced employment. For 2020, Dr.&nbsp;Liu will receive an annual base salary of $441,300, with an annual target bonus of 40% of that base salary. The amount, if any, of such
bonus with respect to any calendar year is based on the achievement of predetermined corporate and personal objectives as determined by the Board in its&nbsp;discretion. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Offer Letter Agreement with Suneel Gupta, Ph.D.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December&nbsp;2018, the Company entered into an offer letter agreement with Suneel Gupta, Ph.D., the Company's Chief Development
Officer, pursuant to which he commenced employment. For 2020, Dr.&nbsp;Gupta will receive an annual base salary of $420,000, with an annual target bonus of 40% of that base salary. The amount, if
any, of such bonus with respect to any calendar year is based on the achievement of predetermined corporate and personal objectives as determined by the Board in its&nbsp;discretion. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=26,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=399600,FOLIO='24',FILE='DISK135:[20ZAD1.20ZAD70401]DE70401A.;27',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dg70401_1_25"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is party to an Employee Severance Agreement with each of its Named Executive Officers and certain of its other executives.
If the Company terminates the employee's employment without "cause" or the employee terminates employment for "good reason" (each as defined in the agreement), the employee will receive:
(a)&nbsp;salary continuation for 12&nbsp;months, for the Chief Executive Officer, or nine months, for the other Named Executive Officers (18&nbsp;months and 12&nbsp;months, respectively, in
the case of a change in control termination); (b)&nbsp;COBRA continuation for the salary continuation period (or&nbsp;an equivalent cash payment if required by law); (c)&nbsp;in the case of a
change in control termination only, a monthly payment equal to one twelfth of the target bonus for the severance period; and (d)&nbsp;in the case of a change in control termination only,
acceleration of the vesting (and&nbsp;exercisability, if relevant) of equity awards held as of the date of termination. A "change in control termination" is a termination by the Company without
"cause" or the employee for "good reason" that occurs within twelve months following the date of a "change in control," as defined in the agreement. Payments and benefits under the agreement are
subject to the execution of an effective release. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg70401_outstanding_equity_awards_at_fiscal_year_end"> </A>
<A NAME="toc_dg70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows for the fiscal year ended December&nbsp;31, 2019, certain information regarding outstanding equity awards
at fiscal year end for the Named Executive Officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg70401_outstanding_equity_awards_at_december_31,_2019"> </A>
<A NAME="toc_dg70401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2019    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
(#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
(#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vesting<BR>
Commencement<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares or<BR>
Units of<BR>
Stock That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value&nbsp;of<BR>
Shares or<BR>
Units of<BR>
Stock&nbsp;That<BR>
Have Not<BR>
Vested ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Dinesh&nbsp;V. Patel,&nbsp;Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/22/2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44,087</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11/01/2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/21/2024</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/28/2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,344</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>09/01/2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/27/2025</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>04/29/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>163,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,896</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>04/25/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>04/28/2026</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/11/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>266,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53,334</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>08/10/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/10/2026</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>68,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>81,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16.95</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/27/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>317,813</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>08/15/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(4)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>36,466</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,234</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>08/05/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>08/14/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,350</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>234,663</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>136,563</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/27/2029</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>28,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>230,575</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David&nbsp;Y. Liu,
&nbsp;Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>09/26/2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,767</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.87</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>06/01/2013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>09/25/2023</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/22/2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,726</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11/01/2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/21/2024</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>03/26/2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.89</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>03/26/2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>03/25/2025</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/28/2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,656</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>09/01/2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/27/2025</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>04/29/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,820</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>04/25/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>04/28/2026</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/11/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>54,166</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,834</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>08/10/2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10/10/2026</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,895</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,605</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16.95</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/27/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>120,769</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>08/15/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(4)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,466</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>08/05/2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>08/14/2028</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>73,788</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>71,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/27/2029</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>120,300</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Suneel&nbsp;Gupta, Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>01/15/2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>110,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.38</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>01/07/2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>01/14/2029</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(2)</SUP><SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,625</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/28/2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>02/27/2029</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,150</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>25%
of the shares subject to the option vest on the first anniversary of the vesting commencement date, and the remainder vests in 36&nbsp;equal monthly
installments thereafter, subject to the holder continuing to provide services through the applicable vesting date. The option is subject to accelerated vesting in the event of an acquisition and in
the event of a qualifying termination that occurs in the twelve&nbsp;months following the acquisition as described in "&#151;&nbsp;Potential Payments upon Termination or Change of
Control" above.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
shares subject to the option vest as to 1/48 of the shares in equal monthly installments following the vesting commencement date, subject to the holder
continuing to provide services through the applicable vesting date. The option is subject to accelerated vesting in the event of an acquisition and in the event of a qualifying termination that occurs
in the twelve&nbsp;months following the acquisition as described in "&#151;&nbsp;Potential Payments upon Termination or Change of Control" above.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>25%
of the shares vest in equal yearly installments over four years subject to the holder continuing to provide services through the applicable vesting
date. To the extent such award is an option, such option is subject to accelerated vesting in the event of an </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=12935,FOLIO='25',FILE='DISK135:[20ZAD1.20ZAD70401]DG70401A.;49',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_dg70401_1_26"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>acquisition
and in the event of a qualifying termination that occurs in the twelve months following the acquisiton as described in "&#151;&nbsp;Potential Payments upon Termination or
Change of Control" above.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>1/3
of the shares vest on each of February&nbsp;5, 2019, August&nbsp;5, 2019 and February&nbsp;5, 2020, subject to the holder continuing to provide
services through the applicable vesting date. The option is subject to accelerated vesting in the event of an acquisition and in the event of a qualifying termination that occurs in the
twelve&nbsp;months following the acquisition as described in "&#151;&nbsp;Potential Payments upon Termination or Change of Control" above. </FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> OPTION EXERCISES AND STOCK VESTED  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows information regarding option exercises and RSUs vested during the fiscal year ended December&nbsp;31, 2019,
with respect to the Named Executive Officers. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Acquired Upon<BR>
Exercise<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized<BR>
Upon Exercise<BR>
($)<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Acquired Upon<BR>
Vesting<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized<BR>
Upon Vesting<BR>
($)<SUP>(2)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dinesh V. Patel, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,344</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>164,869</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>553,912</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Y. Liu, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,575</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>177,460</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
value realized represents the difference between the market value of our common stock on the date of exercise and the exercise price of the option,
multiplied by the number of shares for which the option was exercised.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
value realized represents the difference between the market value of our common stock on each vesting date or, if the vesting date fell on a non-trading
day, the closing price on the day following the vesting date, multiplied by the number of shares that vested on that date. </FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> NONQUALIFIED DEFERRED COMPENSATION  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company does not maintain any nonqualified deferred compensation plans. The Board may elect to provide the Company's officers and
other employees with nonqualified deferred compensation benefits in the future if it determines that doing so is in the Company's best&nbsp;interests. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> 401(K) PLAN  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains a tax-qualified retirement plan that provides eligible U.S.&nbsp;employees with an opportunity to save for
retirement on a tax advantaged basis. Eligible employees may defer eligible compensation subject to applicable annual Internal Revenue Code of 1986, as amended (the&nbsp;"Code"), limits. The 401(k)
plan permits participants to make both pre-tax and certain after-tax (Roth) deferral contributions. These contributions are allocated to each participant's individual account and are then invested in
selected investment alternatives according to the participant's directions. Employees are immediately and fully vested in their contributions. Currently, the Company does not make matching
contributions or discretionary contributions to the 401(k) plan. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code with the 401(k) plan's related trust intended to be
exempt under Section&nbsp;501(a) of the Code. As a tax qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until
distributed from the 401(k)&nbsp;plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=1040511,FOLIO='26',FILE='DISK135:[20ZAD1.20ZAD70401]DG70401A.;49',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_di70401_1_27"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di70401_director_compensation"> </A>
<A NAME="toc_di70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DIRECTOR COMPENSATION    <BR>    </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table shows for the fiscal year ended December&nbsp;31, 2019 certain information with respect to the compensation of
all non-employee directors of the&nbsp;Company: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di70401_non-employee_director_compensation_for_fiscal_2019"> </A>
<A NAME="toc_di70401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  NON-EMPLOYEE DIRECTOR COMPENSATION FOR FISCAL 2019    <BR>    </B></FONT></P>
 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned or<BR>
Paid in Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)<SUP>(3)(4)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Former Non-Employee Directors</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Armen B. Shanafelt, Ph.D.<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Current&nbsp;Non-Employee&nbsp;Directors</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bryan Giraudo</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,191</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>129,032</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chaitan Khosla, Ph.D.<SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>104,938</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>153,688</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sarah Noonberg, M.D., Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>126,341</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harold E. Selick, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>162,591</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Waddill</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>138,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lewis T. Williams, M.D., Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123,841</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Dr.&nbsp;Shanafelt
ceased to be a director of the Company upon the expiration of his term at the conclusion of the 2019&nbsp;Annual Meeting of
Stockholders as of June&nbsp;7,&nbsp;2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>During
2019, Dr.&nbsp;Khosla received cash compensation in the amount of $5,000 for service on the Company's Scientific Advisory Board and a stock option
grant with a grant date fair value of $26,097 for providing consulting services to the Company.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
amounts in the "Option Awards" column reflect the aggregate grant date fair value of stock options granted during the calendar year computed in
accordance with the provisions of Accounting Standards Codification (ASC) 718, Compensation&nbsp;&#151;&nbsp;Stock Compensation. The valuation assumptions used in determining
such amounts are described in the notes to the Company's financial statements included in its Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019. These amounts do not
reflect the actual economic value that will be realized by the directors upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock
options.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
aggregate number of stock option awards for each non-employee director that were outstanding as of the end of fiscal year 2019 is as follows: </FONT></DD></DL>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:20%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:21pt;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,21pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate Number of<BR>
Option Awards<BR>
Outstanding as of<BR>
December&nbsp;31, 2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bryan Giraudo</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chaitan Khosla, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,638</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sarah Noonberg, M.D., Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harold E. Selick, Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Waddill</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>72,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lewis T. Williams, M.D. Ph.D.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September&nbsp;2016, the Board adopted a non-employee director compensation policy. Pursuant to this policy, the Company compensates its non-employee directors with a combination of
cash and equity. The annual cash compensation contained in this policy, set forth below, is payable in equal quarterly installments, in advance during the last month of each quarter in which service
occurred, prorated for any months of partial service. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Annual Board Service Retainer:  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Non-employee directors other than the non-executive chairperson: $40,000  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Non-executive chairperson: $70,000 </FONT><FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Annual Committee Service Retainer (Chairperson):  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chairperson of the Audit Committee: $15,000 </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=911879,FOLIO='27',FILE='DISK135:[20ZAD1.20ZAD70401]DI70401A.;23',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_di70401_1_28"> </A>
<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chairperson of the Compensation Committee: $10,000  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chairperson of the Nominating and Corporate Governance Committee: $7,500 </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Annual Committee Service Retainer (Non-Chairperson):  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Audit Committee: $7,500  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Compensation Committee: $5,000  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Nominating and Corporate Governance Committee: $3,750 </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's non-employee director compensation policy also provides for equity compensation to each non-employee director
as&nbsp;follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Initial Grant: At the time he or she joins the Board, each new non-employee director will receive an initial stock option
grant to purchase 24,000&nbsp;shares of common stock and shall vest in equal monthly installments over three years. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Annual Grant: Each non-employee director will also be granted an option to purchase 12,000&nbsp;shares of common stock
on the date of each Annual Meeting of stockholders which shall vest at the earlier of (i)&nbsp;one year or (ii)&nbsp;the next Annual Meeting of stockholders. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
options granted to the Company's non-employee directors under the policy will vest in full upon the completion of a change in&nbsp;control. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Non-Employee Director Compensation for 2020  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After consultation with Radford and pursuant to the compensation review process described above, the Compensation Committee made
certain changes to the non-employee director compensation program which were effective as of January&nbsp;1, 2020. Specifically, the annual board membership retainer for the non-employee director
chairman has been increased to $75,000; the additional cash retainers for service as Chairperson of the Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee
were increased to $20,000, $15,000 and $10,000, respectively; the additional cash retainers for service as a member of the Audit Committee, Compensation Committee and the Nominating and Corporate
Governance Committee were increased to $10,000, $7,500 and $5,000, respectively and the annual equity grant and initial equity grant to be awarded in fiscal year 2020 to our non-employee directors was
increased to 15,000 shares and 30,000 shares, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=1028474,FOLIO='28',FILE='DISK135:[20ZAD1.20ZAD70401]DI70401A.;23',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_di70401_1_29"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> Equity Compensation Plan Information  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides certain information with respect to all of the Company's equity compensation plans in effect as of
December&nbsp;31,&nbsp;2019. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="106pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="75pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:50pt;"><FONT SIZE=1><B>Plan Category<SUP>(1)</SUP>

<!-- COMMAND=ADD_SCROPPEDRULE,50pt -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
to be issued upon<BR>
exercise of outstanding<BR>
options, warrants and<BR>
rights<BR>
(a) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
average exercise<BR>
price of<BR>
outstanding<BR>
options,<BR>
warrants and<BR>
rights<SUP>(6)</SUP><BR>
(b) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available for<BR>
issuance under equity<BR>
compensation plans<BR>
(excluding securities<BR>
reflected in column (a))<BR>
(c) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Equity compensation plans approved by securities holders:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2007 Stock Option and Incentive Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>627,066</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(3)</SUP></FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016 Equity Incentive Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,862,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(4)</SUP></FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.59</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>602,091</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(7)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2016 Employee Stock Purchase Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>577,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(8)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Equity compensation plans not approved by securities holders:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018 Inducement Plan</FONT><FONT SIZE=2><B><SUP>(2)</SUP></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>470,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><SUP>(5)</SUP></FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.06</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>280,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,960,003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT"  style="font-family:times;"><FONT SIZE=2>$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.82</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,460,084</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="12%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
equity compensation plans are described in Note&nbsp;12 to&nbsp;our financial statements included in our Annual Report on Form&nbsp;10-K for the
year ended December&nbsp;31,&nbsp;2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>In
February&nbsp;2020, the Board approved the Amended and Restated 2018 Inducement Plan (the "2018 Inducement Plan"), a non-stockholder approved stock
plan, under which it reserved and authorized up to 1,250,000&nbsp;shares of the Company's common stock in order to award options and RSUs to persons that were not previously employees or directors
of the Company, or following a bona&nbsp;fide period of non-employment, as an inducement material to such persons entering into employment with the Company, within the meaning of
Rule&nbsp;5635(c)(4) of the Nasdaq Listing Rules. The 2018 Inducement Plan is administered by the Board or the Compensation Committee of the Board, which determines the types of awards to be
granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. Awards granted under the 2018 Inducement Plan expire no later than ten years from the date
of&nbsp;grant.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>As
of December&nbsp;31, 2019, there were 627,066&nbsp;shares of common stock subject to outstanding stock options under the 2007 Stock Option and
Incentive&nbsp;Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>As
of December&nbsp;31, 2019, there were 2,584,455&nbsp;shares of common stock subject to outstanding stock options and 278,482 shares to be issued
pursuant to the vesting of unvested RSUs under the 2016 Equity Incentive Plan (the&nbsp;"2016&nbsp;Plan").
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>As
of December&nbsp;31, 2019, there were 470,000&nbsp;shares of common stock subject to outstanding stock options under the 2018 Inducement&nbsp;Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
weighted-average exercise price of outstanding stock options granted under equity compensation plans approved by securities holders was $10.77. The
weighted-average exercise price of outstanding options granted under all equity compensation plans was $10.06. RSUs do not have an exercise price and therefore have not been included in the
calculations.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
reserve for shares available under the 2016 Plan will automatically increase on January&nbsp;1st&nbsp;each year by an amount equal to
4&nbsp;percent of the total number of outstanding shares of our capital stock on December&nbsp;31st&nbsp;of the preceding fiscal year, or a lesser number of shares determined by the Board.
Shares subject to stock awards granted under our 2016 Plan that expire or cancel without being exercised in full, or that are paid out in cash rather than in shares, do not reduce the number of shares
available for issuance under our 2016 Plan. Additionally, shares issued pursuant to stock awards under our 2016 Plan that we repurchase or that are forfeited, as well as shares used to pay the
exercise price of a stock award or to satisfy the tax withholding obligations related to a stock award, become available for future grant under our 2016&nbsp;Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
reserve for shares available under the 2016 Employee Stock Purchase Plan (the&nbsp;"2016 ESPP") will automatically increase on
January&nbsp;1st&nbsp;each year by the lesser of: (i)&nbsp;one&nbsp;percent of the total number of outstanding shares of our capital stock outstanding on December&nbsp;31st&nbsp;of the
preceding fiscal year, (ii)&nbsp;300,000 shares, or (iii)&nbsp;such other number of shares determined by the Board. As of December&nbsp;31, 2019, an aggregate of 577,993&nbsp;shares remained
available for future issuance under the 2016&nbsp;ESPP. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=912678,FOLIO='29',FILE='DISK135:[20ZAD1.20ZAD70401]DI70401A.;23',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_di70401_1_30"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di70401_transactions_with_rela__di702218"> </A>
<A NAME="toc_di70401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> RELATED-PERSON TRANSACTIONS POLICY AND PROCEDURES  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2016, the Company adopted a written Related-Person Transactions Policy that sets forth the Company's policies and procedures
regarding the identification, review, consideration and approval or ratification of "related-persons transactions." For purposes of the Company's policy only, a "related-person transaction" is a
transaction, arrangement or relationship (or&nbsp;any series of similar transactions, arrangements or relationships) in which the Company and any "related person" are participants involving an
amount that exceeds $120,000. Transactions involving compensation for services provided to the Company as an employee, director, consultant or similar capacity by a related person are not covered by
this policy. A related person is any executive officer, director, or more than 5% stockholder of the Company, including any of their immediate family members, and any entity owned or controlled by
such&nbsp;persons. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> CERTAIN RELATED-PERSON TRANSACTIONS  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of transactions since January&nbsp;1, 2018 in which the Company participated in which the amount involved
exceeded or will exceed $120,000, and in which any of the Company's directors, executive officers or holders of more than 5% of the Company's capital stock or any members of their immediate family had
or will have a direct or indirect material interest, other than compensation arrangements which are described under "Executive Compensation" and "Director Compensation." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> JANSSEN LICENSE AND COLLABORATION AGREEMENT  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On May&nbsp;26, 2017, the Company and Janssen Biotech,&nbsp;Inc., ("Janssen"), one of the Janssen Pharmaceutical Companies of
Johnson&nbsp;&amp; Johnson, entered into an exclusive license and collaboration agreement (the "Janssen License and Collaboration Agreement") for the development, manufacture and potential
commercialization of PTG-200 worldwide for the treatment of Crohn's disease ("CD") and&nbsp;ulcerative colitis ("UC"). Janssen is a related party to the Company as Johnson&nbsp;&amp; Johnson
Innovation&#151;JJDC,&nbsp;Inc., a significant stockholder of the Company, and Janssen are both subsidiaries of Johnson&nbsp;&amp; Johnson. PTG-200 is the Company's orally delivered
gut-restricted Interleukin&nbsp;23 receptor ("IL-23R") antagonist drug candidate currently in development. The Janssen License and
Collaboration Agreement became effective on July&nbsp;13, 2017. Upon the effectiveness of the agreement, the Company received a non-refundable, upfront cash payment of $50.0&nbsp;million from
Janssen. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Janssen License and Collaboration Agreement, the Company granted to Janssen an exclusive worldwide license to develop, manufacture and commercialize PTG-200 and related IL-23R
compounds for all indications, including CD and UC. The Company was responsible, at its own expense, for the conduct of the Phase&nbsp;1 clinical trial for PTG-200, and Janssen is responsible for
the conduct of the Phase&nbsp;2 clinical trial for PTG-200 in CD, including filing the U.S. Investigational New Drug application ("IND"). Development costs for the Phase&nbsp;2 clinical trial are
shared between the parties on an 80/20 basis, with Janssen assuming the larger share. Janssen submitted an IND for PTG-200 in CD during the second quarter of 2019, which took effect in
July&nbsp;2019. The Company initiated a Phase&nbsp;2 clinical study for PTG-200 in CD with Janssen in the fourth quarter of 2019. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company entered into an amendment (the "First Amendment") to the Janssen License and Collaboration Agreement effective May&nbsp;7, 2019. The First Amendment builds upon the
Company's ongoing development collaboration with Janssen for PTG-200 and, upon the effectiveness of the First Amendment, the Company became eligible to receive a $25.0&nbsp;million payment from
Janssen, which was received during the second quarter of 2019. The First Amendment expanded the scope of the Janssen License and Collaboration Agreement by supporting research efforts towards
identifying and developing second-generation IL-23R antagonists ("second-generation compounds"). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the services added in the First Amendment, Janssen will pay certain costs and milestones related to advancing pre-clinical candidates from the second-generation research
program through Phase&nbsp;1 studies, including funding of a certain number of full time equivalent employees ("FTEs") for a set period of time. The Company will pay 100% of the costs for the
Phase&nbsp;1 studies for the first second-generation compound, and 50% of the costs of the Phase&nbsp;1 studies for the second and third second-generation compounds; thereafter Janssen </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=946619,FOLIO='30',FILE='DISK135:[20ZAD1.20ZAD70401]DI70401A.;23',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_di70401_1_31"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>will
pay 100% of any further Phase&nbsp;1 development costs. Development costs for the Phase&nbsp;2 clinical trials for second-generation compounds are shared between the parties on an 80/20
basis, with Janssen assuming the larger share. The Company's Phase&nbsp;1 and Phase&nbsp;2 development costs are also limited by overall spending caps. In December&nbsp;2019, the Company became
eligible to receive a $5.0&nbsp;million payment triggered by the successful nomination of a second-generation development compound. The Company will be eligible to receive a $7.5&nbsp;million
milestone payment at the completion of a Phase&nbsp;1 study for the first second-generation compound. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the First Amendment, the Company will be eligible to receive clinical development, regulatory and sales milestones, if and as achieved, and/or payments relating to Janssen's
elections to maintain or expand its license rights. The next such payment is a $50.0&nbsp;million payment based on Phase&nbsp;2a clinical trial results, as
follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Janssen can elect to advance PTG-200 into Phase&nbsp;2b following receipt of the top line results of the CD
Phase&nbsp;2a clinical trial for PTG-200 by paying a $50.0&nbsp;million maintenance fee (the "Amended First Opt-in Election");&nbsp;or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Janssen would make a $50.0&nbsp;million milestone payment following dosing of the third patient in first Phase&nbsp;2b
clinical trial for CD for a second-generation product (the "Second-Generation Phase&nbsp;2b Milestone"). </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Janssen
can also then elect to receive exclusive, world-wide commercial rights for both PTG-200 and second-generation products following the Phase&nbsp;2b completion date for PTG-200
or a second-generation product by paying a $50.0&nbsp;million payment (the "Amended Second Opt-in Election"). If Janssen does not make the Amended Second Opt-in Election, with respect to either
PTG-200 or a second-generation compound, the Janssen License and Collaboration Agreement would terminate. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company will also be eligible for certain additional milestone payments including a potential payment of either $100.0&nbsp;million upon a Phase&nbsp;3 CD clinical trial meeting
a primary clinical endpoint with respect to PTG-200 or $115.0&nbsp;million upon a Phase&nbsp;3 CD clinical trial meeting a primary clinical endpoint with respect to a second-generation compound. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the First Amendment, the Company will be eligible to receive tiered royalties on net product sales at percentages ranging from mid-single digits to ten&nbsp;percent. Under
the terms of the First Amendment, the Company will be eligible to receive up to $1.0&nbsp;billion in research, development, regulatory and sales milestones. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Janssen License and Collaboration Agreement remains in effect until the royalty obligations cease following patent and regulatory expiry, unless terminated earlier. Upon a
termination of the Janssen License and Collaboration Agreement, all rights revert back to the Company, and in certain circumstances, if such termination occurs during ongoing clinical trials, Janssen
would, if requested, provide certain financial and operational support to the Company for the completion of such trials. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> 2018 OFFERING  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;6, 2018, the Company entered into a securities purchase agreement (the&nbsp;"Securities Purchase Agreement") with
certain accredited investors, including entities affiliated with Biotechnology Value Fund,&nbsp;L.P. (collectively, "BVF") and entities affiliated with Farallon Partners,&nbsp;LLC, each a holder
of more than 5% of the Company's common stock, relating to the issuance and sale of 2,750,000&nbsp;shares of the Company's common stock at a negotiated purchase price of $8.00 per share, for
aggregate net proceeds of $21.7&nbsp;million, after deducting offering expenses payable by us. In a concurrent private placement, the Company issued such investors warrants to purchase an aggregate
of 2,750,000&nbsp;shares of the Company's common stock (each, a "Warrant" and, collectively, the "Warrants"). Each Warrant is exercisable from August&nbsp;8, 2018 through August&nbsp;8, 2023.
Warrants to purchase 1,375,000&nbsp;shares of the Company's common stock have an exercise price of $10.00 per share ("Class&nbsp;A Warrants") and Warrants to purchase 1,375,000&nbsp;shares of
the Company's common stock have an exercise price of $15.00 per share ("Class&nbsp;B Warrants"). The exercise price and number of shares of common stock issuable upon the exercise of the Warrants
(the&nbsp;"Warrant Shares") are subject to adjustment in the event of any stock dividends and splits, reverse stock split, recapitalization, reorganization or similar transaction, as described in
the Warrants. Under certain circumstances, the Warrants may be exercisable on a "cashless" basis. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=33,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=1401,FOLIO='31',FILE='DISK135:[20ZAD1.20ZAD70401]DI70401A.;23',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<A NAME="page_di70401_1_32"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>In
connection with the issuance and sale of the common stock and Warrants, the Company granted the investors certain registration rights with respect to the Warrants and the Warrant&nbsp;Shares. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> WARRANT EXCHANGE  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;21, 2018, the Company entered into an exchange agreement with entities affiliated with BVF, a holder of more than 5%
of the Company's common stock (the&nbsp;"Exchanging Stockholders"), pursuant to which the Company exchanged an aggregate of 1,000,000&nbsp;shares of common stock owned by the Exchanging
Stockholders for pre-funded warrants (the&nbsp;"Exchange Warrants") to purchase an aggregate of shares of 1,000,000&nbsp;common stock (subject to adjustment in the event of stock splits,
recapitalizations and other similar events affecting common stock), with an exercise price of $0.00001 per share. The Exchange Warrants will expire ten years from the date of issuance. The Exchange
Warrants are exercisable at any time prior to expiration except that the Exchange Warrants cannot be exercised by the Exchanging Stockholders if, after giving effect thereto, the Exchanging
Stockholders would beneficially own more than 9.99% of the Company's common stock, subject to certain exceptions. The holders of the Exchange Warrants will not have the right to vote on any matter
except to the extent required by Delaware law. The Exchange Warrants were issued without registration under the Securities Act in reliance on the exemption from registration contained in
Section&nbsp;3(a)(9) of the Securities Act. During the year ended December&nbsp;31, 2019, Exchange Warrants to purchase 600,000&nbsp;shares were net exercised, resulting in the issuance of
599,997&nbsp;shares of common stock. As of December&nbsp;31, 2019, 400,000 of the Exchange Warrants remain unexercised. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B> INDEMNIFICATION  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company provides indemnification for its directors and executive officers so that they will be free from undue concern about
personal liability in connection with their service to the
Company. Under the Company's Amended and Restated Bylaws, the Company is required to indemnify its directors and executive officers to the extent not prohibited under Delaware or other applicable law.
The Company has also entered into indemnity agreements with certain officers and directors. These agreements provide, among other things, that the Company will indemnify the officer or director, under
the circumstances and to the extent provided for in the agreement, for expenses, damages, judgments, fines and settlements he or she may be required to pay in actions or proceedings which he or she is
or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law and the Amended and
Restated Bylaws. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di70401_householding_of_proxy_materials"> </A>
<A NAME="toc_di70401_4"> </A>
<BR></FONT><FONT SIZE=2><B>  HOUSEHOLDING OF PROXY MATERIALS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC has adopted rules that permit companies and intermediaries (e.g.,&nbsp;brokers) to satisfy the delivery requirements for
Notices of Internet Availability of Proxy Materials or other Annual Meeting Materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet
Availability of Proxy Materials or other Annual Meeting Materials addressed to those stockholders. This process, which is commonly referred to as "householding," potentially means extra convenience
for stockholders and cost savings for&nbsp;companies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
year, a number of brokers with account holders who are Protagonist stockholders will be "householding" the Company's proxy materials. A single Notice of Internet Availability of
Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your
broker that they will be "householding" communications to your address, "householding" will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer
wish to participate in "householding" and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify your broker or Protagonist. Direct your written request
to Protagonist Therapeutics,&nbsp;Inc., c/o Donald Kalkofen, Chief Financial Officer, at 7707&nbsp;Gateway Blvd., Suite&nbsp;140, Newark, California 94560 or contact Donald Kalkofen at
(510)&nbsp;474-0881. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like to request "householding" of
their communications should contact their&nbsp;brokers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=34,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=934397,FOLIO='32',FILE='DISK135:[20ZAD1.20ZAD70401]DI70401A.;23',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dk70401_1_33"> </A>


<!-- COMMAND=ADD_BASECOLOR,"Black" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->





<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk70401_other_matters"> </A>
<A NAME="toc_dk70401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly
brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best&nbsp;judgment. </FONT></P>
 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
<P style="font-family:times;text-align:justify"></FONT></P>

<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=2> /s/ Dinesh V. Patel<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Dinesh V. Patel, Ph.D.<BR>
President and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=2> April&nbsp;16, 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>A copy of the Company's Annual Report to the Securities and Exchange Commission on Form&nbsp;10-K for the year ended December&nbsp;31, 2019 is available
without charge upon written request to: Corporate Secretary, Protagonist Therapeutics,&nbsp;Inc., 7707&nbsp;Gateway Blvd., Suite&nbsp;140, Newark, California 94560.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=250208,FOLIO='33',FILE='DISK135:[20ZAD1.20ZAD70401]DK70401A.;9',USER='DSCHWAR',CD='16-APR-2020;16:11' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET Before The Meeting - Go to www.proxyvote.com Use the Internet to   transmit your voting instructions and for electronic delivery of information.   Vote by 11:59 p.m. Eastern Time on May 27, 2020. Have your proxy card in hand   when you access the web site and follow the instructions to obtain your   records and to create an electronic voting instruction form. PROTAGONIST   THERAPEUTICS, INC. 7707 GATEWAY BLVD. SUITE 140 NEWARK, CA 94560 During The   Meeting - Go to www.virtualshareholdermeeting.com/PTGX2020 You may attend the   meeting via the Internet and vote during the meeting. Have the information   that is printed in the box marked by the arrow available and follow the   instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to   transmit your voting instructions. Vote by 11:59 p.m. Eastern Time on May 27,   2020. Have your proxy card in hand when you call and then follow the   instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it   in the postage-paid envelope we have provided or return it to Vote   Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE,   MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: D10737-P38637 KEEP THIS   PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS   VALID ONLY WHEN SIGNED AND DATED. PROTAGONIST THERAPEUTICS, INC. The Board of   Directors recommends you vote FOR the following: For Withhold For All   AllAllExcept To withhold authority to vote for any individual nominee(s),   mark &quot;For All Except&quot; and write the number(s) of the nominee(s) on   the line below. ! !! 1. To elect the two nominees for Class I director named   below to serve until the 2023 Annual Meeting of Stockholders and until their   successors have been duly elected and qualified. Nominees: 01) Dinesh V.   Patel, Ph.D. 02) Sarah Noonberg, M.D., Ph.D. For Against Abstain The Board of   Directors recommends you vote FOR the following proposal: ! ! ! 2. To ratify   the selection by the Audit Committee of the Board of Ernst &amp; Young LLP as   Protagonist Therapeutics' independent registered public accounting firm for   the fiscal year ending December 31, 2020. NOTE: The Board of Directors knows   of no other matters that will be presented for consideration at the 2020   Annual Meeting of Stockholders. If any other matters are properly brought   before the 2020 Annual Meeting of Stockholders, it is the intention of the   person named in the proxy card to vote on such matters in accordance with   their best judgment. ! For address changes and/or comments, please check this   box and write them on the back where indicated. Please sign exactly as your   name(s) appear(s) hereon. When signing as attorney, executor, administrator,   trustee or guardian, please add your title as such. When signing as joint   tenants, all parties in the joint tenancy must sign. If a signer is a   corporation, please sign in full corporate name by duly authorized officers.   Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1208" src="g21042bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=36,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=190190,FOLIO='',FILE="DISK103:[20ZAD2.20ZAD70402]2104-2-BG_ZAD70402.CHC",USER="SSTALKE",CD='Apr 15 21:49 2020' -->

<div style="page-break-before:always;"></div>
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Annual Meeting   to be held on May 28, 2020: The Notice and Proxy Statement and Form 10-K are   available at www.proxyvote.com. D10738-P38637 PROTAGONIST THERAPEUTICS, INC.   Annual Meeting of Stockholders May 28, 2020 10:00 AM This proxy is solicited   by the Board of Directors The stockholder(s) hereby appoint(s) Dinesh Patel   and Don Kalkofen, each as proxy, with the power to appoint their substitute,   and hereby authorize(s) each to represent and to vote, as designated on the   reverse side of this ballot, all of the shares of Common Stock of PROTAGONIST   THERAPEUTICS, INC. that the stockholder(s) is/are entitled to vote at the   Annual Meeting of Stockholders to be held virtually at 10:00 AM, PDT on May   28, 2020, at www.virtualshareholdermeeting.com/PTGX2020, and any adjournment   or postponement thereof. This proxy, when properly executed, will be voted in   the manner directed herein. If no such direction is made, this proxy will be   voted in accordance with the Board of Directors' recommendations. (If you   noted any Address Changes/Comments above, please mark corresponding box on   the reverse side.) Continued and to be signed on reverse side Address   Changes/Comments: </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1208" src="g21042bgi002.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=37,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1",CHK=432276,FOLIO='',FILE="DISK103:[20ZAD2.20ZAD70402]2104-2-BG_ZAD70402.CHC",USER="SSTALKE",CD='Apr 15 21:49 2020' -->

<BR>
<P><br><A NAME="20ZAD70401_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_be70401_1">QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_da70401_1">PROPOSAL 1 ELECTION OF DIRECTORS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_da70401_2">THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF EACH NAMED NOMINEE.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_da70401_3">INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_da70401_4">INFORMATION REGARDING COMMITTEES OF THE BOARD OF DIRECTORS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc70401_1">PROPOSAL 2 RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc70401_2">THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOR OF PROPOSAL 2.</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de70401_1">EXECUTIVE OFFICERS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de70401_2">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de70401_3">DELINQUENT SECTION 16(A) REPORTS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de70401_4">EXECUTIVE COMPENSATION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de70401_5">SUMMARY COMPENSATION TABLE FOR FISCAL 2019</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de70401_6">NARRATIVE TO SUMMARY COMPENSATION TABLE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dg70401_1">OUTSTANDING EQUITY AWARDS AT FISCAL YEAR END</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dg70401_2">OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2019</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di70401_1">DIRECTOR COMPENSATION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di70401_2">NON-EMPLOYEE DIRECTOR COMPENSATION FOR FISCAL 2019</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di70401_3">TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di70401_4">HOUSEHOLDING OF PROXY MATERIALS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk70401_1">OTHER MATTERS</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=SSTALKE,SEQ=,EFW="2241314",CP="PROTAGONIST THERAPEUTICS, INC",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g494085.jpg
<DESCRIPTION>G494085.JPG
<TEXT>
begin 644 g494085.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!)35),3%]'4D%02$E#4SI;4%)/5$%'
M3TY)4U1?5$A%4D%0155424-37TE.0UU04D]404=/3DE35%]035-?1$Q?3$]'
M3RY%4%/_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1" !; 6X# 2(  A$! Q$!_\0 'P   0,% 0$!
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MB6>#R#1C2SENBX<1\1(V2LLH::D6K1VY81$J_=H,W1T0;*L8VAX3UVU<=%?
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MMQUU;[8U5;H92Q9!3;(YR%7F*#*.85^1/GA9P$)/*RD>]6 >XPI$G(TAS<E
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M\B9FA\T/,B3+277IV9;'4( [2'CH@&<!'-VYVK58L<BB5VHF8YQ,\<@9PIR
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M;IH',7GN[3&0(0PDY !$IA$O( (AR :^P. ]@#@/?Y!P'WC\@X^?S_7^O3&
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M3TOK+%$R*D.FH0JB9RF(<AR@8AR& 0,0Y3 )3%, B!BF 2F#V$!#7BQ%7K<
M=PI!P$+#*.Q 71XF)CXT[D0$1 7!F+9 RWN(C^E$_N(C\]>[HU@FFR,'"; G
M&^WQF0BIAV3@NA*BJ/9/2\*G*>EST+SH XT#K@MN]?E;$R$'.B]A[@BH)]5]
MCV1>%]IQGR/&#&13(D_9M7J2:I5DTW;9%RF18@"!%2$7(H4JA ,8"J% #E 1
M !#D>?KT:->D1$551$15XY5$3E>.>.5_:\<KQS^N5XSPI$J(*JJB/*HBJO"*
MO'*HGZ3GA.>/WPG/ZSRW<'#/U@</HF->KE*4A5G;!HY5*0@B8A"J+HJ'*0AC
M&,4H& I3&,(  B.OW".8%=C(%9-"OS(^G%\#9 '@H!QPB+H">>*0<!PD*G8'
M <%]@X^W1KS\;?*E\8=E)"4NH\J2<\$J\<]DY7A?VG*Y[^5U10?D/J@J"#W+
MA!+A5%$YX054451_2JB>O6(YINW*U5S>-E3<6\G*ZXJ=\HS"K1L$W"3^D+-X
MU:4INHX?>:T)%BU.:LNQ+Z=VJKVKMNX@"*P$57'5JO1#IT]BH*'C'CX>7KJ/
MBV#%R['GGETX:MT5G \_^>.?\=>WHU%55#64P2@@L**3+6RNGE=,GR2PMI!R
M9KK1.*2M"XZ9*+;:B "O040?63EYM%SL3D%RSE(XM?14VN1T9;","U-#$:A5
MK#P,H O&RPRVAO.(3CII\AJI+SA\_GK'W]3J\J_1E).NP4C)MP*#>1?P\:\?
M( 01$@(O'+55RF!1$>T"*E[>?S>-9!HU*N--NB@NM@X*$A()B)BA"O(EP2*G
M*+[1?VF0;3SK)*;+KC1**@I-F0$H%Z(54515$D]$/Z5/2HJ90  H<
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JBX[$@HBEQ^NRHG*\?USSQGE3,A$2,B$.>@J2J@\\<]45>$YX3GCC/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g21042bgi001.gif
<DESCRIPTION>G21042BGI001.GIF
<TEXT>
begin 644 g21042bgi001.gif
M1TE&.#=AIP.X!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    IP.X!(?___\A&2'W_^][>WOW[];>[_=K<VOW___FSK7.YO?W[_>]YO?>
M__?O__>UUN^MK:V,Q>;W_][W[^;F[^:,I;7.]_?6K7-K<X1[>X2<Q>8I&2'F
MQ9S>M8QKK=[W[\5SE+UCE+T   "$C(3%M9SWWJVMM:64I:6<UN^]I92EK;7F
MSIS.E&NUM;6USMXA*2EC4G-C8UJME)QCG,[%E'-"C,6EE+V4E)S6M9R<I<YC
M4EK%YN;FYL7FUL6]E)SWYK6<C(2M<WM".DI28VNMUN]*4G.4<UKWWL5":Z64
M<VM:0E+%I7NMK9R48YQ[6DJ]SKW.SKW6UM;.I91C<[6$C*52:XQ:>Z5S:UJ$
MI<YS6EJUE'N<O<5C&2&UC&L9WHPQ,3&MG(PA,5*UO=;WWLXZ2GN,4HQC(4J$
M>Z4I:WM"4E)::YP9$#JUI<[W_\YK8QEC8VN,UHSWSJ6E8YP9G(R,O=;WQ8S%
MUN_6O;7.I1FEQ<ZM<U)SK<[.K;7.WD+.WA#%YLZ4Q<[%&7O6I93.Q9R40DHQ
M(7M:6DK>Q9QKWM:$C+V]<Z5K.C&48U+%<U)CE*4Z6AF,.H2,I=ZUO;6E>Z40
M8QDA2GO.O<Z<O=:48T)S0DH0I5(9$.80I1G.$+6M:];%UMZ$4G.,0J7%<WO>
MSG.4<XP9:Z4AE,40&7MC.AD0[]80Q=8Q$$(A$ C6G$H0YE):$.:4$.80YAG6
M$!D98U*$<[490JWW*8SW*2D9$*W.$.:M4GM2.GN<.AFU:R&4WE)"I5(90N9"
MI1F4WAG.0K5KWE)KWAE:SHPZ:]Z4I8SWUI1:0JW>:]Z<&4I:E(3WC(SWC"F4
MG%*4YL5*E-;FUJ6<$!F4$*U:$*W6$$I"[]9"Q=9"YE):0N:40N9"YAF4I1G6
M0AEKI5)KI1FUE$K6G-[.0N;>:QD0:]ZUI;7%YIR]WG-:[XS62GM:$'MC:^;6
M0DJ,:^;W,=XZ*1GWWM9[:VL9G._WE-Z,$'N4:QECE.9[>VOWUEKWUADA(2$0
M,1#W_V,($"$A""$(_P !"!Q(L*#!@P@3*ES(L*'#AQ C2IQ(L:+%BQ@S:MS(
ML:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSASZMS)LZ?/GT"#"AU*
MM*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7KV##BAU+MJS9LVC3JEW+
MMJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX #"QY,N+#APX@3*U[,N+'CQY C2YY,
MN;+ERY@S:][,N;/GSZ!#BQY-NK3ITZA3JU[-NK7KU[!CRYY-N[;MV[ASZ][-
MN[?OW\"#"Q].O+CQX\B3*U_.O+GSY]"C2Y].O;KUZ]BS:]_.O;OW[^##B_\?
M3[Z\^?/HTZM?S[Z]^_?PX\N?3[^^_?OX\^O?S[^___\ !BC@@ 06:."!"":H
MX((,-NC@@Q!&*.&$%%9HX8489JCAAAQVZ.&'((8HXH@DEFCBB2BFJ.**++;H
MXHLPQBCCC#36:..-..:HXXX\]NCCCT!Z]L 3##U0")%!)BGA TD(@:1!#^P3
M@A!0*&DEA!@$X84(50HTP0->A!#"*BE(-H$-#W1YY9IV/>&&%_O N8\_JZP2
MQ ,30#3 /GSVV:<7,$P1B4@*V&%")7DV!868;D@4"9IL1MI5"2Z(:>DJ+GCA
M0A"9NA%)H@RY8>FHI(90B)H=.1%$"$$\N10/C$;_M.B8GDAJJU4)%%*J%V'$
M8P(,7F@*CQ>CH)J0J*P>8\.R-L0@Q"J6V@#2$VBPZJI2"J!I+$,30.L/#[>&
M&]4 I/XC@D&1%.(%&/!L:H($"R$[ *@#39"#F*U^1*VU8R4@YBJUBBOP4B)
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M\  %F*B")Z P0P  $A-I&$%'/:&$)'1 #*P<@D \D(=6*F$?:.@ 3\<01"Z
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M!"2&-;E0CEE\6O'08BH$O2#ZL1@71PQYH",5%F"$(KAWQC8%P(^#'$@]%$0
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M$!O0!%1@"5AW2"WE ;M "PR #/# K,ZZ"M#ZK 6 #*J@![Q "]7ZK F #%[
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M_D;& !<!K$ )"]  =.!F$2!5OU6]>G"&UPL""* (I/ $[7=1WW:&=8 ,&M4
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M)9 4TPY@-5(@(]< P#4'(0R((:L"'G"C$#="131<<<<EMUQSST57(0%$\"(
M@> 13,\GO$MW+2@&J*Y>???EMU]__P4XQ0E&$6B?(%S8:Y4: QZ+J@H9ACAB
MB2>FN.*(._+"@ =L]"0)O?8!U^*&)C '4Y%/1CEEE5=FN2X)1!A@"9.5XM:+
M3UO&.6>==^:YYY4GF-9GH8=.2PP3YC (@1@<T$H"'NH@8 ])_QAP2  $OA@B
M(0'BJ:0 L22()PQZ 7":Z88(Z%HM'T"IP(,UQH[+B!8:0(:&H!UBXY$ZX$Z(
M )*Z0KL .$!HU2T! HDD 8,$4&& #[SN*H(>UH!\(0'$\$0!OAL28PFD&[)Z
M:80$D/J)+Q8@6MP'G+A;H1B$8#9UV6<'P(,'/H=C"=0?BF"/*P2P8Y;*&1*C
MAZP3XB&&W<&R^H.Q">"@ X<( &)YM8R0@NJY+.B@=;-\,&-OKCR8PNRX;DA!
M<8-ZB&3XK228?/.#2*]!_;2,0,%Z"1"817O:_P=@ ,TEA@= (&G+^D(.+@ )
M#V0A"1<XG@3L8 4JI& /@X"!$,R0@/\&/O!X ##"%UJ@!#0(01X?X $7DO"!
M!-R@"4+X  %(*(0I8"('!DA# @B @B2XX01PD(<N<$ U"=R@$%1H@1B0( 0L
M.,\@!,A"$*90 DP4 @2"*(,0<G "(]C0 %1P@ <6(807^*$,,,C@$JE0!P\\
MP@]Y  ,.O"8 5D0# #ZHAP["000L@( !=*!! P3 " C0 0U)D!X D)&,"@RR
M X9( @4= (=+"*$#=?/ ( IA@#$X0  <2((\"D$*S0$@ G'PQ HRF ,]3( #
M3)S"#U;HAT\TX0@<()P 5F")">3! #E(@0/-, (0) "(&;0$]3 A!"$D,PMN
M>($E7*."',#_@ B6@(,!^ C&",Q 'D)( @44)P 77@ '3T!"!G$P@2Q@ HG>
M(:<5B+#.R4W@"TV@@B4:  =\Y  #)BB"&TSP W=JP0Y(*,0%+"&&'Z!!@9;P
M@ D@ ,4<4.$*WBGB(HB0A$8X@ 1%(,(4"B U'GS!!J-8@ >6( ,C@'2#-\"$
M(H) @PD@( LG$&!.=;I3Y-@.=P](0?Y,N0=$,, .DE!?[W @@"B@E  CZ,!1
MC8I4"^$/#RB00@.4MH#D)2"$0_  "BR!@C0P  &Y&$($HJ '!#"A D9@P@+@
MX,0G<@ " K" #   10,^,10+,,(G/@@ .%2!!X,XP2=E0 <[WE&P_P+(0P<$
M $@V@((!/LCJ08R0A@K0H106H$%N&-$!0!ID!A @P1@J<) (H#5O?GB$X@"9
M #IT#Y.?R$ #Z  "'I!A 7BE >0\P 1/6  $!?  &?Q !K.!+P%LR,5%25!,
M '! "UF8@W 1X0 ?@, )3#B)$1K1@CQ<%!D?&,$'S)<0%5 @$F;0 E-38(?R
M01$1E0M$"B80@[<9P09_",44[&<$$X#5!%J8W @>,,DVF2 #!T%? 9KJ51M
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M5CB";\P!21*V'/@ N].\5Z,!@%O*0OA#5$,E)<@ !8@ ,GB"3_BF.8B 4+B
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M@MBJM5#PI!D040NX A5(@R& +GW:K>$AGY,%@1W(A2@SK@*8-3\8A3"( "#
M@ZR0KP*@'CQ0@FMU/;$QB/;Z@>0S @H88,AAJ@?X AR0P<E\HBQ@Q;I3M[,!
MU02('^"I :_QKRN(* .* '-8V_\\U0Z\-X/H'!.0QOXT 8@S@E(=*D38 11H
M!.(4@!#Z@Q><L:N2@D&ESPV8 B2X@A%8E$?<-7EH!(O[A"G0 AZ(+B8= !'@
M62,8 /[3@B\P 6,R* I8@ERQ 1.0!PPHS*?Z8BV(@5VT@_\EB($?2(%(B &>
M$QLXP #)VH,?V)0E& 43B 03L 32B8$ZN8!C4.(HR+Z6\+\4T!XU,U$'$ ."
MI%9Y<#D=[5N&(4W=Z;/;L8,>"%.K698"@K\!1 !)J "IZC(86P @E2P[(+L9
M6X#]^0%Y ($R53-F([FV^JY&.]#1@8-9@ +OO8'B!"$R4#4($ ,R2#-#X#,C
M> 2JF;0=L-]P,-.P6QX2T+N$<%TXB#1&O  DQ0;G/;55"[Q RIM&\K2[*=$G
MUJ<=PI(3L("\S8U"334]O('CZDKU'1XP?#49\(,X*%[K&E40F-'J&J*]BH-L
MXX U^ (\*( (2 0 5J0U!KXHJ+'_Q &>!!H^"BB!*<BM^?%ALY$<#V4( ?#A
MM(H? -B#?F,JI+(=G )2!_XR)#" 6'J!HHH'%,@^/# '"K #&Z WD"N!SP&>
M'XB$+! YT$.!%)0LN[WE^_RD/]B!8/H#'@BJ):7:,#(!3[H!?'A$Q($<HV$]
M./!C!]@#)Q"$$I $ ": %#@)U%V#,(B:-2"=2*@!L?& %(A:DC"'3>F=-7@"
M%0PO<_@M.U@# HB$-3""$9@"<Z":"(@$AJZU$0B6.> !.] !.TC12$:9]5.I
M.4" ^CF(_FR!$DA1K[TZPOU<^/L"!"OE$7#&2IB:'$:!#Y@ .T"$"4 !"( Z
M?Y8>JV&"_R> 2!Y<B'C( RTP6T'0*P)E AV('A(PT2E80&1C0F&3 @%0 F8
MA>:LU\7!+/D1@".<'T:80$4R!H/P9D4*K0C@5X!5".M%W?F=@$+M,R1P1B!H
M >@:@*2; T,XKL\3-L(1WDC<[QT8:*:2)A+X $%P@Q/%MJR(@+)N@"C4 A3
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M,D(\Q),+RH;0@!7\[I]^((,#(K#-A/B "0Y AB)(48 -S($#("@ '*3@AT5
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M1PR(QE?5DE=J8GB M\"CA0=D #>2< T<EN")*& AGW90$S,%4(D%*:4'\KB
M$R#;K-X*(E 1&,'@F*"5 K]D6?'X EFR@P\I/$'! A $");5LVI-8)_(D$(4
M.O_ @6@0E $24 $-1.&Y%5AB97ZM3T*P=@)W?C1X*M"/!#[JE&-<H@.,R"@;
M0I>0( \'&23&B%FQ0,L> :$I*V!9!)C  1H@9 :6L.@,,F"'+! "#SW0P0SF
MH("7/2$.=6B !TK"4GD5P%P)4 $%$B"0!KQL7 D1 PI^4+8XA*&Z>D"P2TA
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M=9P>X 83.(&KV0%FF46@A-S@=()6D%R#Q84'S( 60-BD2 $/6)@AR,#'P8]
M>80'7/\"$=#5/"U VC& /LE 3JF$!+C8M3"( /C %E#9E.560Y' $33 U@%9
MZ B .]&!,:A$0[U$* 0, !!9&R;=2S09 *S UY&!(-@/7?@ )M# #@P"!BG
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MS# *4-<_[A8=Y/_+@"1'$7D9J % ;C" '2R!$]A "P" '=B 5$'$?27.'O1
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M"I%2H'#SH>!! >;"-##H(?]%"2T.  CH$4:K.7,_M/B),<6!AP>26DRPDT+
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MIE B( MYL("''S4ND >>5?Q918TJ)D!!$7C'B(0+,/00_^"&0M(8X5XP0"C
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M+ SA!9+Q0J-*,\(4"D '5>B!%Y1PPBE2" 5EC:$%U;+$#;10_X"5E4 1A!C
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MPRA*<,QC:Z$'B&A /);0B![4R C'R!4!]G"%=T;!5E RP2<P( (;O$4"]D4
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M!MP@!W+ #1,U B1A#3R6""A@W3Q6" J!+#P "&  !G3!VO1+'CZ!,"!K=!W
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MX0,\P+U00 \B8 0Z\WN1N4O_.D=U53F:OD 28LDWV!<!>@ 0UQ>7M! %D&
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MJXT?R-? 7/ !=3.^Z3^@X.>TK*7!]XE W,:'LN%@6V=)"V[ YE%'=A/MEC9
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M $;(,$@8K^9  3=D7&TH804$@P+LG#TH0/9JW0D)U/0 RNE"-L%'1HC38J$
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MD+% !"B $,'?JW[6IQT@># "!)[A@8(>#2PUQPA'!!A*W/\U0,(C0_\L=Y)
M="[ PX&KT4&#(=$8Y,,C)TA 1RETT,) ;B>H, 8#$S!R0@0+"L#(;"MT8,'J
M'@S"(@"RX>H4[P3Y8%8$@YP  !TR^$!& BO%+;UWJ/- QK%2[/")"(82=&U4
M]+(1_D!T!'S!D7&@,,7G4:3   <4</!!'0+D@0CG-*(.!  "'KZ@A1V,8@U7
M0<;!.#"%>DD"#S<P00)ND((* 0 .)G# #*90@ V(X$@]P$$#?& #$TSA!'!H
MPA$<8(<4W$@ >XC! R11@"C4 "SGB<1V7I0X24#A!W;;@ TBL00G+ $2@F-2
M06H3 R?\8 XT-(/(%A Q7H5MBUSLHA=%4IO_'LP',C24A-H8 !X8D>8+/@,
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MM4%O#K$Y+PB$02B$0V@4 @ '&',%4$!Q0F &2I-$W>$!6^(&*?4#5Y,%4I
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M U?H/V%6(TL628-E95G 2_\1($PP:J=! #-  4.G M>#!+&WC >)D E)@ I
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M $V0#!OC!8T0!EF@"':G!!H !HZ#B6A("7_@"5*:ET:@"/NPJU.Z"Z3  Y=
M"9Z0!Y3@!Y=P!!/PK-%*"[9F!,GZ!'90 72@!A#  :IP MXZ!Q: IJO!"J:@
M!4_@ #ZP!32PK#3@ XH@!>>@"-%  #WP!"@ #U-GJ/]*H+&2B2E#!4XP%J 1
M 4H@7%RZ"&E0 <N1!)S9)S<0L;YB+&(0-#: "<%D>CAW+F50!5EPK"3@0D\@
MK4Y! "O0HQ8 #T$ HDO:I%'*$)Z1!4%@I8AR!&AX!$]PJQ.@LEJP"\8@ *P
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M"/)@>R90*5JP0)/D+4T'-&F7!GX0!9T>0*M!;=3#02F0!9#Y 3R0!3!0!2V
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M)V^XH@ +6&ID30Y2^ (IF"0R8@H_).')" K8(Z$L.PA<*8$(=FH T!^TD$J
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M:$<]^E&0AE2D(R5I24UZ4I2F5*4K96E+7?I2U+1G$<R8PE9 ,P$>7*PT$D#
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M 5>ZBQOX! &Q <7YO/1P-FAKB?9B B@8( D8C_8@@R7POA\@$,BX ?PHDD=
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ME_R8@*&\ 3V8#B;0 2ZPG[44RP7JKP00A7O 1MSKB'1;  E8@:A91 90@1S
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M_S*A11B^$RVB??.!)A@ (4B&"O J*L""(2"!'/B (+Z!$;U<@,,1%2 "($J
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MHH@-.$B!7T4-_NLRT1%VUT" !\AZW# 0ND=[ ;>,"ZBNZ<B"1C#!&<@!(<
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MP03=X0MI% W<C+$1G (<"<$Y39F,'HKXP--8P!5,0-5DA=:<PRS4 0E\ )M
M4<W,@#P D )PP!H40"1*1 0 @;R(4$\1E3F@  9\7Q2,@C+VU!-X$<4]P!(
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MW P<F -1(4(\)H 'E  DO8LD?* GN%4*P ?(Q2.MH"+_G1% "5! N9S+%*
M(HG CY)FF[KIFZ8&"?QE1<21 G3<'+#2Z37C;X$<#RS!="# %YA ;\R&&3Q!
M#$ < $A % C!%=R (AA7ZHB9LJD+NSQ!NX@!%W@*!Z !"$PEO"%A-+C*+.A
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MB)E 3T3'%'0 &]P%,PS!_ F!%/@!9AE M>3<E!YMTB8%7@Q!I@K! /R6D)W
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MW9M[( $((, '>'*Y((=_<D<>@(&!\(5L1$&JW( Y\?$>3P0<X!/_;+GJ%T9
M.& A@$\$,J!!-/B (HS!5 C(SQ0UAG#1S"RUK?IJ!+'!)5AU;0M<R*RS5F,*
M0%41<U,*H,=XH1LZ&/O+7V":N=B!0<O/'EP!50R 08P G@+!7[AR],B/4ES
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M B. G1B84 =1W"-H A##(@P  8%X  A#((@+NP>"H)UO!2>@0Q"B$;OTN;
M,_A>00BP""L84@)Y$&9!Z$"#@2#C"'KD0@?8  KI)1$4.R2A"0% AR.PX1'"
M1 8\2*$T"\PAF,?\(%.TYDED2 %O$<C%-@%@ 1GPS )Z4$$58 D$K/E AP#P
M@1EV:! !S  ),OB<"%[@  !$(!21&(78LNB ",R 95/XPA<'(H -E/&,6PP#
MRIJ8@J!MP 1.F(+H!D* &-C !E@#P U,4%$%QE$">-Q!#&8:NQ[4 &5B\*-
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M<0IUL.\F.VFTNXYR(!$09=!BJ0<[?(  7\@L<&5) !1(00"&:-[HTF>$1RR
M *,MB"$4T=J"2& &$$ &#51PA'Z28 M>_O(*.N"#>%9.'B!P7SMG"]+[??01
M?C G< LHD/019 40\*TYZ "&.?C@<1Y  M2@VY3TH2Q]'HQ=,B4M@%"T@ 1)
MDVZE+9 !!=A0:3Z0!P8T)ND@AP*K6MC!59F Q!E0( $D,(/?Y"$\'& 1"2^X
MPG>IRH$!#, -%-#!@%L7@Q8?^ M:6/#H?I"#N[44#F; _T'0_N8&)%Q@"-V3
MQQ0"3&P$B'@@8R6<"5KPA"P((05/J"@">E#6.9 @!I%8 EL#\0D1X.,#=WQK
MRNP NZ71C@,O$,$4MBD!O :-DWH80>DN4%'19DP>'8BE)V7'VP8;5LLM54$.
M7G#GT<W@!%+NWAQ&2X(DO("@ W'S @3 BF9^= 9I<!\=,A9@;0X$GO \I\[]
M;%L!!-H'R=@!)$B@B&C<8 A9XT $&ZT4 820NC0(Z$"/>4$N3/>?.Q1 +HHV
MWM9%E(<]: $/IH "/>@@#D_,@Q P\(,@?&#5=5!!(QR@Q$C$  >F'FHDL"B)
M%$B"A0)(A-@$0H><[I0@;*B!.?_P[KX&P"&.OS0!Y0)A C^8H\-WA&KK3$S5
M/6AR#T"@P!#HD(0J-%4@WW9")#K@9 S8@*UR]< 7])!)'AM2EW?-:TM?.3I3
M'EEME*6J+)>6!2E.F0!*  .I"W&$ G#@Y52U[Q/(X'$P*[.9<'B!$D@KA1U4
MGR 2*#2I+T$+7EO@'M\LQ4#8_,UWIE,@Y>RMU($[4#;DXAAS(  A33#GA/*Z
MZ8SBSSXJ%[3@A*I@SD2MHQH@ F*(NA!0HF:!9R9*@GCHT@@@#W3A#]@@#NK
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M$VY@  Q@"K1 #)# #>3!=S+G&!:A9B@ !10L96)@#:0F ^! 'F" "M80#D3
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M5V%DA'[H@QX C#[D!Q[P.5X-%!X &#[D \ .V'SEG_]>( : YZ=>($3 Y ,
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M@Z 3.S9A_WDNH(@AM@ &/0PE' CD #PN.(8$<& +S<MCL9)BA%VXH%(ML4
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MZ,!#JFB3&01ABI:RC0.,4(11ZD% 00"!(# AF9M<@@H.4$$3B& "<SB!B?
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M4]%A'T@=BB>G_Q=5"!@U&FS8!2UX+)CJ,12M?]C%+2H0 5X08@@^P)^G+ !
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M ]0U 7DP!DP"0EVE?X"(!6F0!4G0"$C@6B*)'4*D2O"C@OL0 "Z0#/^(!HW
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M+]'C&'!E/7YII/S:K_[ZKPQR:NSG?@<!?T5%8Q(W!4L0=T?!?[PAB0O !H/
M2<1&"13P X0T5HR05JY98V^'EB@3$\1V5R:P$5[0:%AWF^T7=6S@IY]U5X1U
MLHWU6 X !\=@ K=5/J<1 2O@!126 #)T6ELE7QQ0"+7E4PC0@ZM5!E1@ [!%
M";*%$+1E6R<J@Q")$CFT5)Y <VGP "G0 END"[VI&/>U#[?QF/ S5F:H0F6X
M7?\4\ !AP$1HP"AWI 9DJA%3P 5&^P?NM4LK$%Z-$ ,K- </ZE)Y,$I =PIC
MX+5A, &&X%]+( *$= BV9P%IE1<3*W\C*F2N]&L6L \5=F$,Z:)>]0.G<)M>
M::]36IFEV!(P-@5>6Q$;^Z$S9E9&( \R$*0 N[N\V[N^BQ6W" _0"D&H2#U-
M2G]8MZ:%=!K4HYE46@'44Y8R48\\E1@J< IN)603BZ9C.GB*04"%JKQST!ET
M$ 3^Z$EP<6T@H!(B-D1S0&N1=0;@Y#[DTX!/2C^0,+3Q" #(@ EG8 .%L IM
M.EF%8) YI+QI@&2V%T3[($FE4P0XIT)J\ '@U3P3O$?_<E>FEQ!(X+3!M1=&
M4P0')K< 9=L\!]I$.E$?'+PZ]C"96K!%?!1H3;!(+A _]Y4,DO9(3:=(:[I@
MBA0 ,)G ,1)7Z!55(* $F[M5+<<*:[I)13B!6Z"MJ]1K8A43*T!C'QMVKAL
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M<< C2A(J>.Q8H>*)0Y,Q>"H]&8&%BI9*GAH P(E3!18IYRX%H+*  R89/(J
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MBK1X2B "+@HIA @(&LKA"@^*H$($+""<(8G@*",1 !46J:( RHYPH@@B3 /
MD":DB,VW#3"1XHE+]AE#BQ&2:&1"W,A#,TTULX-+!@$$@*.)5<!HY!(T%"'E
MP)Q\&$0&!# )@A)++$CB! [0<,.+?5:198L@'%$EI7""".(L2PZ#QX4Q'' 0
M! 06@0<-+^IZ*@)&"+OK!CG!T(.'/((@2;4(PDDB1P#AL *B)*Z0+C<[S*D
M 22$D ? G.#X8?\( K*0(@$Q4*  A4CR((*"2(H0@M@3C+A$""(&&$* &Q81
MXH(6[.AD@BAR,"")UIKBE@AY]!#CB\(0( .%0M+ X] D#) A0"Z(L.(# L(1
M@@HG0'FBB#&FX"(X$AYA\*X-FJ#BTH&M"#@GO(+SX1$=-@9!@"(;<<"')MS
MLJD;+CDC S'(S6%'1F 8PS@ Z  #B9R1(4((+*J8X),6&J!COIR0B<:'3]@E
M@BD.A"Z$AAV8&"$-!_ R@8P6C)#'"B%T:2$*+12(((X6''2#B!;@X'!-N>>F
MN^ZL)G!C'R\BL;LJ$<)S0X&GUBO%53"<4&2,$BXAY 16]+I) $8("=?_ C
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MABQ00!).4"X AHO5>@W@ DZ(PKV8, $40(  A@C.LOZ0A1, ()-5L-=DR,
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M55X&R@$DJB '%[!"H',B 9H&@!^&AD2D-:(?Y=BA!Y&(@63$\  ' V #/Z!
M"GIP@1)D@#2\3?>]C_L$%&QMN'9XEQ&4, 4F -P@K*G871 PBA:((1%[#%<>
M*T ;<>47?%J807D; H*,.[("NZFP!:@ "IU)@ X=D  7RCN! W=6#[FHP P
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MXG5I6",B<)=5$2XB#76(PBFLNH/")R42D>A!&%#[=O8G!QF*B 9;!W&&.LP
M'F?_&8)T) </0OR!%?P'D VP/1Y /4%X,A,!MK%X-BLPDKF@@BPH!,&Z* [
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MZ:27>GKIJ*-N^E12N>ZI(F6=Y06KH6<TB@O[R ,7K8,,Z\.R":"+H",!K!(
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M 1<3^,$/'!P __! TSU>%& $BLQ!U3D3$U2 7OW!"OQ!U.U8#*H) 2"!FT1
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M#4'Y&  6$($#E)E__QZIG_XIH :JH"HA<$[F@F94'$7C-![%A-8!K[A7RY2
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M%\B#$,A&=T2!/! !#IQQ&.B5*#W)#<A##C1"#)B&%DS*!B!T"8Q"$QP3(A1
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M'"'DN8*#,? !8;B")+A!CZK@P (?(M*8@(L3#)$!@ EF2 *?(PKP8!$JY%E
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MK$ $3HE .(CP@K<8H0D**H *FD $"("I LA  Y1 P!$+0"D)LJN*&!9A@"1
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MD(.>SP$.;VUF8(U082>\C"&-+?(%\'"??L;P(NZ[0 Z-P+_Y3E)^ZX'$!."
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M:!$)!4Z$@@@#)-C8PQH$]/# *(-U- 4. MR0PO^!=D$2UAH;&=08'D;8,*0
M&4VPEP<F9"#& U<@\ !_!0F@F"4(V/!'( 9Z\, <!1& @IL B($"7!G>B6>>
M>N[)9Y]^_EF2:JRY1MH4\/@C#VVCY;8;&R?R)I94$4C"%DH^4("8"BF,H$<+
M/3;@5@E3P&5'"7:($)T1)L"U09(&!9+"$R: E]<7G\0(%H/R?+"#.5_&L("5
M-3R!PG %&9$%%2EX H =DC#@08)O2MM1G8!>BVVVVF[+;;=_;JA4:4A!)=6B
MU@% 0B,HSA#&7P3$4>E);J&%5:P4X/%IJ"(8(,(4>!1 P!<F/$'!$ *T>B
MJMH0)D>-L?5C#9[888[_#N:L(0@2S/PP11@(+"'FL4O8*6P#\40B)YR5 8!
M# YZ"W/,,L],<\TVGR1H:Z_%EBAI @ 11@%T1 ?I;VDA8JQ)Q3E 9L>7XI'(
M6&XY02E'9HF*%L(&19!%#D1']!\D!&DY1P0]2-(K#D8\\'++(2N\V)@905L"
M7@@JZ$$/'Q!V<]]^_PUXX()/!6Z'HSD50(BD&8%$#FD@)L ,&1#$@19/$H>$
M&YA0,02H%/A!J><M(" /#$2D\,,G;B#"0\$'NSHF!Q=D0( D.)2;=QAC!C*
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M$$3><* 0,$A#"SA0!")0X LP@ $56G"#:%:'AV%!PED(8((P!$P>0K . :)
MSD8L#Q,__, YV7F? HBA.8T8 ARB.84G_" '.1#"*B-@APO8@"3(:H2<!, #
M%#CH!IDY"9Q.T) IH#$);BCCFU19$#'\P$ZU[*A'/WJ__I%F7 .PXV>(6:)'
M 0 9:>A<^WIX@P%<@2R]20$*U,60*&SJ+)-BB]G6$(,:[* &>(B""1)@-A.@
MP 0.,%L,?B")!/A@2U$810+_/( FR# @$))P@@AHUP-$@$H$<H+2'D91@CDT
M! @F6!G+%,H;!/0@D0:ATQR,\ 4*H* *#9BG@TYYQ7.Z%:2$+:QA:W;+P\7&
M#;OLC ]T P V!#$"0+B=94*W$@\ (3H$L,,Q/J'72)"$  SZ!")&0,0F$:1)
M.["!%AZPAD\!8 ,Q,,.0-K $,PA32UJ(7@/^$P,3N.EC#]@/ =+:D0<,5I.1
MJ,$#:L"#&E%K3I\$  \D8<R.),L$+1  1O/FH A@5)-16.YASXO>]/))I(=[
MR@ D(*)SP8AI,]!*0=@ K_>9Q$21"*H.HE!4RQ$@!HCX;R0B\0"D]N@O3>H-
MQZKG_Z1F?6$*3Z3M% ;3I3_T97KFL %%.';@,+&I,FPJ:T$BL ?6Y34&?HB3
M03YF'BL]ZR1T6AD!,"J&!A5$ C>XXCPYJMX@"WG($4JL:";(6)\!38\4*, &
MDGFTI*'$ U/ &F5K@((42 =32L1R) H0@1I4Z5,>0,(8M&!4!9O J N00 ]B
M( GI:<D2S$N JIR GH6T+ %.9  <?K#*SEXA FB\0K2N2"9@2< (/S"O04A)
M,ASKV#(8A5-#B8SI3&NZ,^P5S?]*6AHCR ,+5<@A16T@ DM,X :64XD*Y.$&
M(5BB "C QQ;G, +17L9X2;C""+3 9]G^]"]TN, <)A %*_\4* %RL<(+IJ"#
M/4PRPP**]15BV,\/@,D\'MBG-2'P9SL18 ]&&L$ &&...8@AE$8H@@&\ Y$<
M=\ N(%A(/$IY4;Q]P0$W  4#T!@2/1 D$*"HP*8/CO"$X\3(H1&!^AJ+FO;I
M]UIXS4!&Z"J3>3I:)A-7N,<_#O*"=+KA(()OA8S0 HCS20"!P,(/U0H%C,N$
M  H)N<UOCG.:,!PTAG)ASG\.]* +O24C!PU)33KTI"M]Z0K?^6=@$P!=,GWJ
M5*^ZD(O^F?\90.56[[K7OWY"IWO&*11$.MC/CO:T+Q#K8P<1U]4.][C+W6]B
M[XRA K"^N>M][WR?&=L[0]*W]WW_\(0O/(7JSAFH5]#PC&^\XU'S=\YH7?"/
MK[SE+Z\3Q&^&[(O'O.<_#WJ:1'[S;@^]Z4^/>IQ!$'V>]@+>S9[ZV,O>\:.?
M2N!GC_O<-U[S4[E[YW4/_.##O?9,<3@ A8_\Y'^=]\57'^R5#_WHXYSX1?FT
MR:6/_>S;G/E%03+EM0_^\!^6^D0Q/JC%C_[TJY?[Y=]'U+^O_OC+'X7D'\JG
MGS___.N?@^P?BO&3O'\!*( <5']",4'G-X )J( +U'\&^!0 N( 1*('E4X!!
M87T3B($9*#@-&!08L%CPIX$A*()]4H% @3@(.((IJ(+7PH$FZ'Z_MX(Q:'IB
M4 2KL IJ_U %,I<2\1 ..*B##$&#8_ R)\$#=B!E4#(#&G $=<$%8 !D!M%7
M1L@19-($8_"#)E&"/_%I("B#73AX/H $1# '3W"%@P0'3; /8Y!=<8$ 3G Y
M)A%%8[!Q"G,):0@7-22$<*@$8&!>$F ' P$3+?@3Q@>#+^$#BA  -N@/8( /
M02 #;V@2'I '-HB#==!Q*$%(2;!&4U8$\' $*,(!I^ /JP &'U ''E $8T K
MD20&85!S?O)%3L@9$O $0V(2$T 'B@@&C,$%-@@&(,  !, +H^@/2\@0"# 8
M)+ %I8!_FC2)I%  A.$#6T *R@B-+N$#I["$E_@9'G )0LB-7O^X+65&! YR
MAJ2X1LL4!&A@45-X2>[1 =.3!:?@ NL( E&P!0%0BA.0!T1@ DV !O#@ E6@
M S, #P$P!O@ #Z08CR4A (9P"F/0!-$P/5P #T&@ 91@)I<0 "Z0 QJP#RY
M Q:P"HNH;M_H!%L0D+\(B261A3XQ05M7$PB% (HP!GA0!Q80! *G$A'PC5IP
M"4$@-C*Q 9@  BT9.[]S.1R0 XT0"440!(V0  B0<BT118P4CNS#!6JX&62B
M"#2@ /HE '3@ C( !74P 8S@ A_P!%R@"C+@DX2 !US@!9WD =- "@PPC33
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M4+ "0DBF0X"VCKB')W"K > /8^ '*+D%&PN_0WB+J_<:+^B=8/.-[B.>>B
MC* +%2PV*\ Y;\((L1$ 9U '7* +X+$!+RP *T $D= $GX@,A7"4*E & RH
ME[D]<( )C8 "4GLY&R"U"B  %I $4Y"*3A"&)^ #GW"4-V  A4 $'_ 7E]%K
M(R"UH"(/:>#"(# !**"9B' @-;2;/O #MPD'^' !9A8L<("N>ED$&6J4.X $
M0F"92="Y2= !NBP%3$L$-I #")LL)3 (1U  ";R5C,&P)A"C4I P/O"-+O_\
M!PH[!!*P 8[("F-P L]Y! :G,(.@!Q([!_ +%X+< 8=X!&EY!*"B"(A&!QH0
M '0Z F#02:R@J[S@?@&0J ;!!HI "]>[C&/9IZQ "V"V"X )  K@EQTP :Q
M".8!O"6 J$:@"*0@L0HBF-*@"" 0#D*0R'EP!.>@"*+ZE0E0QK)K,#1=$#[0
MQU(%G5$@H Q0SADP6\2<!W6<QTE0"*H( ._9"$B@HJU6$&Q,N7EHPC-39FWL
M Y([K2(Q KML$NU6LSRPU4)P#&50!=()!LQ0FGF !EKPFI@@!1-PF7H !5"@
MLQEP21A=$CPX!CC@!W:@N5Q0EH(0S9[@"8;0N!+_JP?4*0,[D <7.P;H&PT2
M +Q/Z))S)$%U=!,D:XQE+ "R^PQ>X'[[0 B[ZI/)X D(D,BR.SD.V@A9<) <
MRK)4X)[PZ<B$++]B\YX?@ *,]"18,:X$T)I:T,L32@7)4Z*-"@;K.%.\H<=S
MP 'C"@<M7,H-89Q02P#-_9Q)08I48 5I8!ZDF:YB\,'_* 4\T,LMT!PX;,Q)
M*P7 G$9'S ]J0 0^S*^2W A;Z0# 79GMY@7\^B:>&P1'\+[F#  <L 4RT(2@
M&LU*$@Z44(4.,-D*L %>( ,@30,[8 _^T*@N$ T&099^BJ@$$0&\0 @ZP NW
MP ;0*R9W:;U[.;ZHR0L!_U#0![U2?3KB&SV^JF "IT *1H"H%J *VV/A^JT(
M>I '0K"^('T$)GT$#%#&0WT"$< (_3LVT;P !7P$<3T!\@L>XCD%X3"_G4T$
MA:"K#7#'[C0"30 &6C"/,DX)0-F84]VM>=#&   'EP"DC3#-1OD^6($)%@7+
M%* $\. %Z_@!7+"D1YT"12 $/IRNC-L(' D&UR8-QEEO$2$ B-SDFN2Y**T*
M09"&>&"?1+H V7T&2 "D1^T'L>D$7J#%V9D2V]D3/0>!- &>9+R3QZH+#P"?
M'O"* L +8T !A7L$NUT%KRL".-N:?%RKWD@%>+ "R/LD<% (EJNX@PO*'IX$
M4O\0N5%IFGL<39@<F@XP 3R  'W< L%Y2=K6QT[P!8", I\ R@0 !>"]$;#<
MI5E0CA, !3P@L'(-N$3P!\_="%O=WF8VS.I]S$UPP41PKC*@ /'@"><0S=.\
MDY>9HS9Y D]@!#!K$"KPL#* %5_)FF-@UVC0SEM "Y1D"%L@DIF.J#P@NR=
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M/DJ6!!BYM ],H2,, $QD" 8"00ZG_(&QU$!"%@V$\.39%X#2@HD Z*CJD)(
M%W@!P'QH$($7K0H^=M&2.-$"_SQ3@K:4 F!!%00!C *LHC1P(C*6 "*LB-G4
MAR(:TD[1**!"$;R9#0"0.$6KSE5*#JYF511Q98<(C,">:CK1PZ @\%Q462 *
M#4T!44Z9O!(A7!DO^\8HY* HP!@]'O* 3>,'YL,Q6BX=<=*$BM.4H46/)EW:
M]&G4J56O9MW:]6O8L67/IEW;]FW<J\6$"Z!F3 :QN87/GB!OGY=(PV6+B"E/
M@7+HT:5/IRXZ H_-/:MOYYXZ@B<&T@8=<3"13=L"J@6LT'6B^WOX\>7/IU_?
M_GW\IQ4,V+?/7/Y1^C/@N?P*-- ^"92 9PR4#G00-@\NT4"Q%H+S81 :ZE"/
MD<6">__P0Q!#%'%$$DN\K;CCDL-/!!?VD6<"$V.4<48::[3Q1AQSU'''[O;K
M[[\5^QN 0!Z+-/)())-4<DDFFYP11>3RFR(F-V!T\DHLL]1R2RZ[]+)$'_W+
MC[]]AOSR3#335'---MMT$DH5[V,N@!?=M/-.///4<T\^9PL3R/L"W&? /@LU
M]%!$$U641SCS8]%%*Q>5=%)**[7T4MO^=%1((C'U]%-00Q45ST;Q&\6+ *H<
M=5566W7UU1PUQ8],,V&U]59<<]65NE+OFY+.2'<5=EABBR565CDY-7999IMU
M]M)>[1.A/U6?M?9:;+--$UG[!!U  FW#%7=<<G6,MC[F]G'_H]-RVW7W77CG
MXQ9=(8.-]UY\\]4WMG/IFY9.=O<5>&""\YV7/F_M+7AAAAN^MM_YIE4W8(<K
MMOAB6P^.&)XR%<;X8Y!#'HV +$Y9Q9]53LXL/>$D8"AEE%=1HXH$AA- C$M@
M3MD%\FB#6+Y'UZ5-!4R$2.(#EF';X)@FB," @@0\3 V!.B;@((4$#$'B PU%
M$X '3PB(88VD7;OA@?),(^")!.Q8(FW4&H C!M!(:R">)PK80Y*R2Q, CB:B
MD7KD$61 @(D$Q C#0PDX*(2('&C0+K:73IC CIH]6&-PUD@X.C@$!A+%&,Y%
MHV., ;:008'23Z.#J](FH$,(2&#T_^&3 42X8H+60[NYA:0)R .&E2<20(DI
M-"29@JYE6VB*%@BZP00-"Y)''BJTZ-OO*.3!QXTKMC<>;_%;0^"+N@G@0<,&
MQ$ !B1R$L,$$]*>3  $'Q,C"/=(6(J-F %1.;5RXB&U>USN[K(%UK6'#(QS@
M(0'8H0X4.XT'F- ""HH&&2"H0W#@T @_,"$,&1S.!-8G-K)%1P <R$$'/!0!
M+NAB#@B$C1$6<80&4<0*-!..![C H-!$Z @ C(W&Y.,M<,U& &(AP0L>.!L5
M0,TU$>C!XHP7!3R4+C!KF$ B-@<; 6S@ 40D#0(>4#?5(& ).>R?'211 3O,
M@H8!1($0F/]0@=,08 0M(0@"/D @"=C!#).[C0> @!(X2&&.I)& !?A($$>J
M)!H"0 T=B!*!7"Q@D:%!1C0\1I!0#,%"9B"C:NB@AZ2=L@ ;H$#2/#"*,#!
M!5. VVQ(0 &G;" 2-1/ 'LS!@ V8H)1^"T0*"@ '$[#1=WNH0?EF(X8E\,\N
M*'"/&+Z@S.$0( J/+(T$Q$ &0JIM!M)4XNM2XP,IA/,U$0CE)E/"ACAT4#5P
M  $12<!!^'A $M&CCF2H4$L J  +-,F- &Z !1E(S8=$0"-M!(  #$E- C,
M0T-;\[/X8(!C0K.-#T#Q1-FH('P>R((;<L"UB9#  $EHQ AR  /_(N# #DT0
M@A:B8((E?,(--K@ 8Y('@ W(0P@E& 5-A8"( A@!"4F@I5BT*0\B(.()2TV>
M'<9HB")$M0#ZRP$5;)"%'#1B"6CCJA ^P(-G0 Y\'BR"$(20!B?T &D(^,$0
M%@*$0I@@!H. @1"DD "2)<$-HDP)22GP!:38X8YZO =)DV %(>CA<$Y8Q!AP
M(!&2%K"P>1""&SXP 0N,(0<Y, !-03 !1A3"K0,0[!Q(9M,DP!4)1/AL.(A
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MP1S@8(!"[+<.)/B '^+0 AB:-,$^0()JIY  I087#S<P*8.[+.$$1"$2=8B
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M1?CL!(T/9@' ""QB<\CX<D&T,(..3.241(H+&*[ KH(DH;<S:.7,<< !+4B
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MP0',1V" 2$J)Y'M$ %@!"(!,J7@$ %(N$5@$&6@@E%B/Q/J")NB Z7I%50.
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M4<"!06U40T5411V!71* 1# '<\ :,1@%2(C4U"!'<TP)*$NG3-U4(/[4VT"
M(IX(4T75UE#5]T@70G$>"T"#"Y@"6O(HUE2Y#;B"!("P'$@PRL[5H *Q1DB
M&QB #_B"79+(YYBENMF  9@",]B<$<L _W(#(NCHJ?L!TI(R^"&"*[B!$J@#
M#I"'0O@,"+N !_N":DU/DB*M#]B!$@CD])R(*7,K;A:#8^ F_R/( F:0A,F[
MU\C(@D)P ]JVIJ/<Z2_( :'R0O.*K*3DO*UAO!MX''Q0)!\2 GDH7HF=.G"R
MV S 6 G0THVUO1.8*"HX 3%8!#/P@^PJ!#(4*/;B'UY.-.X[/DXZ*16@KL>$
M@+@0@L )#F0@ B10!3+T@458*>"P "&P@D* YL,T!"%8!!A(KZEP RSH+0$
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MR)X'!=B1]*3'$(U&PE&QDL023)\'$3#!F5& BBU"<D""28#+D:8&Z02Y"@&
M@!5H<D 0P&B,E3$B/>0I=,2!T[IV[^+-JW<OW[Y^_P(.+'@PX;H2HIS:YV_?
M*A=C+"GX*\#()<:+5X&IL@"PF#P!_*UB[.*(R+L3Y.WS$JGPQBGP]KF)S#HC
MG2LH1PKH$4:JQ$ I"KCD_3!"C# ]=5J:3;:2).$3Q7S9'.]+A[P"Q#"IX%/,
MJ 4$5ER0XK6@!)ATDB6@0Z,!FT<+! @ P/^J5-GJR+HJSZ]_/__^_O\#&*"
M Q((D4(,.33@0OM<)*  "!0AQ <(-.('$)BD,8(!1&!A@#PPI$$768$TX88E
M",ACA1"6$'!A&BV09<<B+VB!!"9""($# QWE,,5F '@0A1!I.&&3( .X,84#
M)" AQ!0F(%$(%8B(L=- <-AP0DN2.%$$$8@P<(,5A5PP!P*72(B2!UDD,44+
M$.*(P1 $1)&#4A\\@4(+2HR1PP!Z3%"G 4E((15T10$5E1@1FI& 3$D,  (/
MX1"11@$(8.*&&T(T:2D"@PAA0!J.1I&$&UHR@D8:/Q+D 1FED2!>1"HD4X$%
MU94U%EDK1"- +IO_M:==@<,26ZRQQR*;K+++]G5::JL-* (\ <@CFX"U%>##
M!Y[D<04#/KP8 1(X3,"!%K=%$08!H[QDQ!1X9('(;;E%4D 6-11  @5X](!#
M;C<-1$!QN:40PTL ^#!%<@618$(D)F00< PX^& #!39DX,$2D!"T1PR1'#,'
M00+LT=P>-CCQPQP1F%/#$S]XUX,43RSAQ!>--(# #P_ 3&>A9!TZ$ \Q>!)%
M!Q*,  )4.!' P3T"W #"$[DXX $7'0C @0P(?#*$ !9$0T)VKGH23G4&$?#%
M!S!-]O-#!)@=P0H\ 7#K0#ZX%RQ9OS+;M]]_ QZXX(,3?F!#!(["D '6_P:H
M @4)D*#'$Y)4TD#D=4202!@-!!)):3*MP8,>=&4>B22;CQS(&A.XU( 8%)1
M00L-W.!YP#6$\2\"(L@+QP.?BX$"$E-$DD+$,<;PP#$F+/&>2Y=^(8\9D?3
MJAA+5(< "B6@\%[)+3- LB1^]-!")!R+D84)S0%@1QR&1D<6 CW@H837")!1
MPMF'/LC$$[,P@ !9& +2],"#J    688@0P:0( 99" +=!N( #8@@D_,H2FQ
M&L]7CE  "<PM,G93BQ[8\PCM1" 4"^ @X5KHPA?",(8RG*&S5$,@$;A@'_+
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MNLS-[@9X0(D FH&''8QB<^[BU\$HJ+H)#-$(%'""#5!G2]S]"R=&,($),-:
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MP3>B 6&^46A1 0X\5]1=P01D01FHR!7P &I1P1^X1$'"@!OHPA6DC3Y:@A&
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M,]"-K,Z5#>#!'G@>0=A!_I&,.?A!"DQDHVR "2P '#A,&QW61!' '@"0!\2
M'D1!=WCA>!# "$Q!#%@"R70'2.K!'I@!=S4"=73&&)P #WQ!"K /0<!144!%
M B  #E(0''R" TB8'N!/!2A7-%04&4 H!X! UAR-V703$^A *&A)$W+ $0@+
M63#LQ'X+**#@K40 $&R&W:@' -P'&PP"3Q@A["6B?*R'7[X=QZ;L0+A* L !
M/)!">G0 '4@H$SHA ,!!B A %FA!U.3_B]8-!!OD0E8XGA_D KE80)9R  5\
M 3]Z43IU; M8 &%&P"BT@"%< >04D;M$@AGDSM7R'1QD(9ENU@V0EJU&E,'
M!!NX[3JI#^28@ @8JSR:@PDD@ ^,P@?802%A2<I<@5<T3 O\;0643"1\P69%
M 1Z%3&Y\84$800R\:PR\703L099NJW>,@![8@1E<RBA 'E!T!R7AQ-"X5!1(
MP;?>@_Q0&- @@0YP0*&L(<_.PA-TC81U@ ^0 0,H@"C(0*M0C85>G11P@(=Z
M !.,0#1L15JLP,T6(AP<@0#0076H  VP 2;P!,X:P0MHQPK\U]T\@DBH!P.\
M;, LPN.112AL_Q87B QDMD 6'*$7,8$@-$I9\&+R>H+B-8"KM$ 46 +"%@ ;
M(,$5",+75HBILD$<P A"D(#6@2(:>L"[  &8P,$\34$8&$&.7JCE 0 =F( G
M""L#&(((# %>/<#$$,P(F#"<J>)L*%@K:@0 @@"E% $81,(@ ./=- %I^.)<
M    ,H8IQ"#LZ<8R<I.[="Z,!$(29<T ( D%Z$!P $ 3)\#D#D\D4, 06%%1
MN(M"[1-//%@4G."^&NL>]  ]!L?S>, #3($?>=$>X !RD(7'I$ -S-46O9T
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M'R&N)+1,)B\!]WB/Z5T'"HC  &1 &%8L 7@A4 #0M^K!($.':2%!S;T/ /!
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MBH0\Y3-!=/'=R YXR^M?R0[4O(L\NBWDQ@ 6O'<-.$$*)(<%M8 1E(#AQO]
M 7A,?O/LQU2/Z_'2#UA"\)P  L1 Q6)NE@(X 43"%  2<]? VY78\/& Z,94
M!73$6$2 A/_343=%9YR!".!#$O#@%[BA$3"!'SRX*F$'A*K UEQ "[1("Q!O
MK$S \S+B5 _">XO 'S "%8C #^"@W3BSCJO']8ZU;#CSV[K'(QZ$!>A!D2_A
MC\Q ">SU88'*PO!O,9$R7V? 7S>A @A $\^  4S!%IV5J,8I657A!]1!9'<P
M'K !EPR1OCB "HC "Q0Q_HF$%;6 "8;);T1 #60!,QC %N$!FJ^VF+TP:^08
MQ]E%H_+B"MAV!@CC&*1 ).P")12%+^XPIT8"Z1G_@0TDYJCNAIH'L1XX00;#
MW@:<(@&<#@J<8N:8@,%D#6F9P F[1-8PPQ!$!AOTBP(8@21D !F3TSN*1+,.
M094(I^<%@N7"K V(7;7BP(/58;9ZH9HP5,",0"-,E/@X4"3H02 T1TOH06=0
M00;< (:4QK>>C<Z 'Q/@JR0_2!Q\4.<&[&$,W]49K 186'RIE$\!E0YX+-LL
M.WF %QV4 I#@\B,$$"-@3<K:S2'J3='J\MYLQE6#PN%!:#C(@"\S#"9@[R"@
M02XBPVPS@2<H00:8^UP00"C\09R'GM%2U 80/^8$]GA$8MB2'P?<1"2J\^,P
M/!MH[==H!D'0\P*0J=<\_ZT@Z$$#.U'7.]'$>'VAWT25Y#Q"UX Y1(+EWA(B
MY']IZ(0; D2/-04,V6AA)T6!/34BQ1@B8,\4)TL60*S1 (!%!@A^9$ @J0(
MD03L(!)@1Q(# B/TE,0H<N0>,R_%?#FQ\H.'+QU$"D# ) &!&2=Z(B 34L -
M*3RR# %@A,P3)@62RMA!)FBX:'2B/?TT9 51  I(2!&@HI 4!BJB1<@C%H %
MGC#E J!#@\VCD%Q]@*H@@%$IF#X>+;!+@P 0IS![KN@003'@.0T\D&G!93*
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MNHO9%B(G %X(QCUV0(^V.%BP&<'$"$TP0 Y:T  $P%$] X/_"0<HMI[-X$\
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M!+Z3@(=_=?\^1@BARA(("[<20 <PX&,,"9CH8"[P%9&L0 3#4T$2L, 3Y\!
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M.@ 9U(HWI& '_((K[D)W,((5_D O#@-YG$);_]H%(TS#-,[L!%[B60P#-#)
M+M9) .B@2N0J%>-')"P "?ZQ-AB!"%HDG2QA-.+ "2Q-)**@!"R# _Z -@*A
M!)@@.7P !$;@ RQ$!48!.-)C@@SK#0<#UZ)@ $1#>9[D)#P2/![@*RG#!#(
M+=NP:># '/S '""A#?L+ =YR"<(&:\SA"L+O 1;Q*8#RD\)OJ8P !2RD,'F
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M.*Z5-R2".02@.RII<*= *K^C#K]RGS9)#%+@QUA5C%12BZ@H !Q)5EU#G"Q
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M7RMB(9*BW()CN+#L2^SN3UKF_$XBQ1; =YWF;]S  =/F J9 $AI@_SI@<(7
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M SD "88AAA;E@H]A<YHQ@TK1&S 9 ;F0'8U0@S,1*5% *!9Y!1S0" 24!U>
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MLB@$5) XKFL3!C B+1* 1N!)/;5.0B /EA /)2!.1%$F7X K0T  D6 E2%0
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M3=P747 (NND15: $WLO27AYLWZT8O9<9*F &0V"A?H S # =LB,3:MX^]?$
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M!@R0NFXL'@"#XC>N_Z@_$0=08.L  -P2 T_)8$,M@ (,DYI&<.1H*@;B6T1
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M)AP@( \8TG" !YH@%3WP@ L&T(4E^O>_T4%$ !QP PRF\ 4M3& &;BA$$D"
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M'YC@B1G,@0$6N(* ;C<"$+R-_VU7..H5_A:!.+0 (AS0P@BFL( (A((""+A
M!MBFA;\)(! I*  =**"#+""A"BT@G I,$(DI["T",1!K#\R!@A1X(@8X )('
M8F ""EA5*R0H[ UL$(EC6 ( =K"!$TP .3@L80DB&)P(8_"!!C3D?0"(@#D0
M,0(F)( $/SB!!Y;0B!)T@  H>&(,/#$"ED2D(39U( * @(=A/G863W@&2^Q
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M",.6$4"!$DS!$K]#W@^F& 4,O#HK1#9!#&H@B!B\SP,F2('_"1R+@"P^X+-
M?, < (  8\=Z !_H6P6,X)".3/ D=I!$)"3!@)3T& !U1-P$C+"$45S "7JS
M'A#\T(.'0/<8+/& 3 +W WSHP1#E%0,3&$" &0 0T?.5R%4D(%]1E%<"*X#
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M.Z!J@9YZ'16X@ 8"  _8J G(@C 0@_,AGC"8@*IRC$#0@LNSL420,2=S @/
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M $"6\"0'VH!HD  E(,?L8@*L*#AI.#\'F@'(*::LN!R4<R^*"Q^O0 8OH$$
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M)$@#)\@#(4 C!Q #6$(C[AL*2:)"(F@*YNJ !I  VB(!3!@ 69JN[ DX!A"
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M C] RA%D6V0  3^H*@O0L0@8!17ZPDN$"&2@@*.B* ?*@C4(GA9 Y$QS,CP
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M<=H$P*K*(;H7L(0=0 1.0X3WH4IM4[*N4 $*D"X*_^"N&ZBT+9,&$9 J G@
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M[?:!-,#;$32^]C*>E*NH%?B#7#B)%5!),MB;![N;(/4*"TB"7[> (%@FB6<
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MZ(@X$I4&&.$+D?C" CY:4 )@UP!0D<I0M/ %+SU1#\0A"4K#,H3@R4 ,0A6
M(#K@ R1,Y&H<Q!0<7F ) ?S4#P>K)!DFH#^!+ PQ/CB8U\"6)22\P%X6,!T
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M]9C,PC5<OG#8,;W$#2 !(NR$$$C*$RS!*AV4'S!%(1@ R'6 4'R! PP$$8A
M/^%<"J%4/&2!"G8 AS6%$+#4&.!#(ZR1$.0B 3""$+C!'$00 _31XZ3!!'#!
M8?@ "N8!0'G54,F)!^2!6A!!5D 5%@FA=1!!$\# 4VG&EQ%6$IP& ZP $G;5
M( Q $@"4!3!$(1A16 D!/CC1#)".6:U !K!=&!G $7B"?V"!4[3 W $,!Q@
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M!EB&Z5\D+,(81((Y# +RF$'_ B"0/$!"1Z"!&Z2 64:!".!##F3 (+F!'C0
M B!.$@R G-BJ?#0.,R!!]YR1'DS #23!^NP %Q"!9!@!)DC*".0 /D1#E8XK
MN99K[+GHGI12C.;,S33 =62'F"J!);099(X"SL"!%!T'!2# !61 !##"=:I
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MP!/R( 3?#8$ .77#%)S A1Q0P D]*"%"2S ((>C!!T@@PA3.1P [?(!N'Q
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M\!(A5\**A$ >/J#W:H#DK, -= $1/J[^W"L+4(D*3N")&@'3)E,(+B ,G@\
M$*!WW*"04$<2G@ ),& (Z&@11+,B(;"/GH>GN" -HB?"@L -CH!GZB>N.-#J
MK$MQT*P"N. PCZ  [G&CQL *JJ  5  $O$21!J 0?HEI;N CS8H.[&T$Y $+
MQ@"8%!,EC/\0*TK "S!C?E#"!V8!V59"!;2M(@0@,3+I);(L,<L32]CI<F*B
M=,*N*SI&D:)G/PV4(102*\QA((* /3W" H0@(D]@?5!"Z!@)8X3NT [42\I&
M"'YJ'U=" ,1 0_?""&IH0U$T(28@":)C+*! /5>A1E)T1FFT1FVT0* @8%Q
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7>9W9N9W=^9WA.9[E>9[IN9Y9.2   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g21042bgi002.gif
<DESCRIPTION>G21042BGI002.GIF
<TEXT>
begin 644 g21042bgi002.gif
M1TE&.#=AIP.X!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MX1TP@0BV(  8-& (%:"T"/:G24&(X  ,YX(2_H#2EM8#O%#_$( )QG& %)J
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M1/ %"Z@&#4 !RO5D@D!: T%#6&4#+* '-) '_D8$4.!E?Y!$8_1*I48%5&8
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MW,M)AD"@G6H!F^2+TBL05ME?M=JKM)F[DQ"EE"40$@ "B2=@?#=X48 !H10
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MP&$.&;(D8YQ:]6K6K5V_AAU;]O]LVK5MW\:=VS6E+(0,%*%"R 8 1%EX1 !
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MA0?8WD%D[]\OPQ=N87P_-0G6 ,&$W^OGOW__;VM !_@ -"((0@K2^U\"%;A
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MS&#&JIO\$C&?=N*K#A#T4[K@9[, )U *.4'>0WLHCX%/34\\(IA] 69P)>M
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M/ !$#$Q#C.L.W]HL(H"0QKFQ 6 "[*,K%$*P9;"")L"1,AC!!J  UA-!&,$
M_T%*/O$ ,A^#30P(F8TB@^!JP2NA!)@X  3#%&]2O\;Y Q0J@!$\@(P(&0U
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M[8.N_3.6ADSIEE;B(-.'BZH"T?JZJ)6:$7 !P2D#*RT8'W"!&-AG2%-)S?
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M"GU&$,B[ F-AD2M< $@ T25)B"53#"Q<6&;&!Y(+!ZRHD*''$@\ %BB1@P#
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MDD$!%Y#$ E# $_C#8V@R)W_= (2RSC5$)UO7)&/ "RP8:6F!R)6$%7B!??7
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MLDI(@ X\@28XQ6XKP+\#@*]C^+:7LA-T03\$0&1?=5W;R'FK 4]#P!Q@ !&
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M6[=OX<:52[.,%T$X4JI<P"3+#@0%*@2 $*5@I"P0.C*<2(6$A[P%=#S19 .
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M)C'SCD;_H. ")%@P1Z+Y0X0* ((<L$<^2/!'I7"V$ -(H ->>,(;0L %ORU
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M0&P7]HD\.B.=VE^]OY(;8/IG(6PK">* ,HI,26SBAP@",$Y@,@!#$$0 PFI
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M#;&D,B)<$T>R!#2^ PL"8#/7Y"XU;T7Y9S-3)V,&0 )0;PM]<&LX("00 (,
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MNWRK%$S -[#@P80+&SZ,.+'BM5927'5I5\.+'6$76[Z,.;/FS9P[>]XL($"
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M8%&41@^@)_K%O  TD"@-4YL$;Q)-)97 0#08D69)#1$10 N@+V1!$$0 #_H
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MBE):;"C QMPP;50>8%B[%A )+:$MG0HX@D[*D 8[@ ZT61 $'S; A5AE84L
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M$(4P:DZ!6BPU$5RH<-3# 5NT?@+Q?0:P8S.# #N&B.=G3@CV3, &#AWG9#6
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MLW^ET7]=F;L]8X!_&Q@2P+(T8$UOXJ-C-UK!Z[S;,AZH.[BJ^[S5:[W7B[T
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M$-'G1]AF8=&+402*,)1M@1_S*\,! !AU04L*)P\WP  4O1 =#=5EL0!Z8-4
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M/[8J% @@@?MI*^[XC0!&,650Q 7LL0E'E<$-S:K.!.2TD>]HI :$<%-T!J'
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M0@,DL(4T_  !!7A #%A0A0*Q  0%,IA(91*&LVUF )" F@4*L4,++ VCS6F
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M@+&U"FXB?\7 Y38R!#<@  \*J+#^;H" ('"%LK'9&"BSXA7%\'9WL?6!(AC
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M,"[(R\C:Z(( 6"[(BS#-  Q'H2X;$JZ^*B#M "'>4Q,GB $;XBX5_]$#+J
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M.JY:G8[*B;I1+?]+B[5:49Y(BP98+#F1![,;@>1A,YW8NMEP@ J  ;!;)CW
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MD< #&L"!U/T"G** 2"42" 6=0-LJ74F Z0BT%ET,$,@\L*0YZ*&!6:%17L6
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M"'RF0ET+1.+X GH 85<:-T3%@B)2(W)#9QY+7(1N95(&9G<2:X""<T4L00V
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M"<Y1F1J4T%22JFT$;NC,-J5*E$_.1 F$&(D\W,"78QZ/!778@9PB<?\(' #
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M%<R -H4!0574UTK$\_4;9$KA,CKS.VG:5)@!V0P4 T@$.@V!%QB"$-1MOUF
M$L2O*H\4SZ1/3G$"KKAH!Z4 0BUN_\B)#@?0!4V$ $6L %,BA,']R9!ZFS<"
MEFTT  6I#1_+(AB  ,UU@E[Q1$-_$PSPS,[)%7X8 /<0,\78'=GAQS'] ")#
M:4:X 5S.A&7 Q$AUR_$4'Z&1(Y<NP)FZ!)8"3%5XS"]%1 K 0%'_;G>H:5:9
M[TQ0P%M1A;8J@G(<TQ&<3"0 3VQ55P2400H<;4CBUE2\SVY);EF$A0*\7?::
MA=S%#J+*)%W<17:L"P+80Z:Z!+3L=75MP1/XPQ'P974Q'V%BRQFP0?PJ38U
M !XP8S FP0>@#^69IP9@@>+L,CRRJC:F@= 8B18$*1#5RQ&T*8M%0A?@PQG@
MASS$C5!H5/_K?0UT1(P.],A+L(<"H$<$&2OF'03Y/,$9> !26&")H,0-+28+
M5$"-O$$8[4$5!$H2M*46D>OH,D8/$,*%U@@4) FY,(8=',\602:0/4<%[/5E
M8)^>5($QW5!!,(0(B(<\C(F.0$ 7^P 1)$$)Y"(2U(A_21*&.IJ4['*%Z'<)
M1, 07$@ W <1=9M\1@@*W($1K$$:8"" MP4>"%\(A$ >10D&VHV&-P87'%,S
M.4EFZ(CZ68 <H*HN+4,LU@D*Z,,#V 9YT S6/,R'T)6W]$ (F#*8=,L3*  -
MC-FH=,H3DF<%]$ ?S("MP5IG $B-G,&6;8\<=-.TL#8-].Q=HNK_ $#-%RS#
MH< 2@[Z H!!;<_? %U!;H]A*;?23:N&%'4"! #230!Q'$L2V2\@#EXR-J(5H
MJG! !BS!%EC$PJ%T-EG(A3,0)%1 %7P+:EOUMZ" "YSRAN+;0RA-A-  2_-$
M#DP(!<0OA!^)"\B!B>8BPPU R\C%#LR*+H(<$D3,&F",EW- 5+0+8;N&9%B
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M!>>;'7:$$= $%RB10S1TF2HX6 _W_GWS:Q]58!!\7<:%<N\2PDQYOO$U>/D
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MM&P#:I@8 -:<"32UPPEU:KDBEE@TDCARO:P>@ASG$H#'-ABU+D1^@&F P><
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M/X2EC52G#P-I0+ZB,-*2_O\S O) @C]Z\ 4<F(FH;[!D:S#PAW=^T@J>"$
MOG!%@BQHKCWX000HL(0J4*$'D]K,"(@:4FEU9 91@$03]F6!._#!GS@XP$A1
MP(%G3F E%+Q0 PDQ (0^DS(&.F&,.@"!.]@5 ".%0"$2U$VZ8LD"!U& 2BP
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MD3R.;>D*P(3*>4X-=A$(@O<0@PC@@9E_0]U&/$<43S'3QV5H@H9CY(1821
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M$&V@BK,G;B.H0HQ7X*_[2& @90CJLMBPP,94+($4:$$<0'U:Q"[[#DD[EQ)
M904=T BA1Q#.$'Z^GT-(R ),N"(%5R8!"!I  F2 30>R>B"=<S8(?0"=%6;
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M0C>B0E7 $NM)^FBIX3A"Y8@@ ]0"Z@*(0^2A&/<#'C&@#]8 #^:*/G\@5R0
M1OFO8LI#LTC_ H!X8#\F0#,ZK1R$X$ LR.FN2(2\P)6XB!9%1@DZ*PCHSK&
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MI#%@P& +="X:SZ4]:(@3A\!",\?DPL)MN:#E#F!^?H;68B 8"^!L<:.\/FD
MPJ _7%088<X8F[$!($$.HN 5<:.FNF*:WO]I%)_T&WD #C5FJ_K 2$>K@6R)
M HZ +HI@SMRN.S3$ +0C#T8@JT9F$/8#M0AB"#270_#Q],!O!$BH(YH@"D8(
M-9(N:;Z-9]CN "R,A<AG3HFW2GZN869&]>+( CSA$'B@9$=@$U##B1A@!9I
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M!E8?D,#J0*;P=M<8 AD\6PWX@;.IX6!2)]!31$HI<1'X8JSCD\,&F# %V$8
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M0,,W>J(S(9%/'9)/6M5-3M E]Q8Y4Q,T8V9$/#$U[60,5[( >! '2S4]2E0
M1K14;!,%0U00$E4#QJ!B?$)0!)-\-34@E"@IHY@1Z<83=A$%&!!3!F%PH4(!
M4Q W[88!RC '<F,J_U]C!!&P!ZX20R\4)EW%$X!3*&)3$J#(-3-W!4WT*T!W
M$*"H.=>8C:6C8EZC!+/#= VBC:_W #H0 INB 0\P!QTP.Q*@CHH% $D!!F&P
M#!'  FS !Z;#+B\W*4876SS7=E5P!39@$2.@##33?.ER>4VW8J<5 >0X!V'
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MP1CG.+41DG[,6H >T.6,%(+T1GH 0L1:<!#B!#2JX;.(,^84"7ORI%"  NL
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M.N@3 + ").@HE#$83@3)5WE!&I!%7LE%&$S,MPF;-YC)5R&2O@HK.S 4?!F
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M0CC4W_@*)VC%/6FAJMG'7/E)8"0R:SD6.RC*+CA/-D "T>2/%X@P%DB/*=@
M(ZBT!I$'*H"- ^V"9A S)WB#GR"$4^H!"-B "E  7&JFU(' )DNHOC( C- "
M]VJ0H)F3<+I4=%H 6KJ SLT &MA4*B!##<B"(S""+7@"8,*F+H""*2B$+EC-
M$","UX7=+H") <"#$_@#RW2-27T ,YJ3A.J"+Q !3GU0&_"!/X""U&4C,0,$
MWK7,+QP1%D "F&@/),C"ZV+>U,V".?G"'^ $&'08>>C>:MW*-,@!U-V ".B
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M(0-%-5Q7L :?GX[8"&Q(@!0&,(07*,8(&Q J(.P@L0BXUA #L( G6K!Q)+1
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MZ8ALLIL<N6:>I,IF.@<6R4 <I&93\AA?1D<0XM9-KF=AUL7 2:B%7BAV"$
MA$]X@N5UD@;S )7/.4#.C(GMB951*NA<2AH6M0 0*"A34H()C-I@^D"4)1%'
M(,()$.5ST(<)T5/W  @5]$,/P-:R6:4I->ASF$P+) O^*!E!^-X4X 2 %FCY
MS.=CL4 %D&9U+DR%.L?(309482B9;F='EH5D#F9T_B9U8I$6&!HB],@ ., S
M^&=&3-=G%J7)<*ES_X#7F%R)F<'H4B*2^M6H".:)&VR1*?F$<W!B+KZ&#( @
M^40-%D !'PCA%X"62<H:=-2%#,X2$5AJ%6S&&R1H&V%+'$[J"#0!C5(64?P
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M>X5%=_\-4-VGRVY$]&B!6_A %DC"&KQ !AQ$69CL"_T!#\A9RL(&?!W)LQA
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M8M^.4J]$2 $M)E&5+O0 ?P*##2)(9:J'_V!K 7KHPA>NL(4_)*LA6&C!%1[
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MO&I $!(@!P!%79[ #@1@@>0E $@ "01!#0 A"1(@69#B"7I@*X3C"?S!)2P
M";BP5%@,$#J#,FH@"T* "@( 8!:  GCS#0:A :S@#T+@#Q3@O R .MIG0[D
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M*,!C#P"Y;,"U8F !R&@"%J9>1_-.CTUZ^J%Z'L_:EDT[R4NO2. !0" +",$
M5!10.J$.)&$(G@ 9&J B!"$/)@107!,Y%0 ?%()6 X &U !J_"$)K 0ASN V
M)X(2O/6M2"4":/3H?"4K(&)8CL 70&)97 MH0<X? N +=.8/!E<-"D / J<3
M](!P*:/_ \"%(0!!"]Y4!F" .FX@"CYB;E46N1!  XR"48_NZ"9@"\ EI()"
M<MW 1UXS"<2(:QF3,)42*+TN*\'Q'1W@>[)P371B5#A"'K!@;B?%-;4 0UN
M)B0@$M!E+,H"*;( 4,SJ#VZB*EI@$+!-0@0!4)RA!7C =9LC9KE B=H%9^G
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MA!S4   ,3*!-:NH;$^Q6A*H=T0HBJ).;CJ@!=>TPB5<P(A< H $(@"$,&M+
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M @Y"(P*$%8%WB71&8FJ)!2!1"(#)P3[YL9HIOV0G#)2 B%?@PAWWDQ]?C!8
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M&-H\"2UJ@71A)/0!.V9IA"TI@#XX4((&/2B)*VU6L4;]K@?E!Q+ZH:%%'8D
M#23@"G=@CWM8VVK66M)$#>+A:'W@ C?(D<]X: (?[H"%$O^LH-5WW "SH9L)
M3@R "3-PP7YM,  -7 %7([B";O_8HCOE:9AB_9(2VN +1=X)$B[($SD?< =C
M[Y? W=Z""]XC@IBQ9)-):C:<&H"G PSA 6#XMRO;N(4J\ &^G.B3 8;I >KN
MQW[Q9>@'^-1P&$N #55XP'Z&F0<EA,$(]?!! OAQ!TOJZ4TOO2,GE&&$+83
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M50[G8',P B.# FK@2B-8=2/3!!\#)E4W.T>@3GJ0-0>2/&L#1S- *W+6+?P
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M8 CS?0@?0/<>HLO2V[%26N\PP0+6Z]_T!,"8[8"[DM%RA$#_@?%77NC8_.C
M![ZLWRZ9#=H5G^1ILBW+G7,5P-MI4@#;BTN*V\&L&[=G1\[^;O%,-S1$H.?)
MR[>GFP+Z/=R=/]$0??(*_@%64-[C6[0P4 26'@5/:^@^0.">7@B@7@,R4 )9
MW0+'XQ(&3@*SV\J"P.,T+@(;8N M[@-I8.C%N^ 6F0*&,!^*"Q!'/  @:,
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MI!%2,/]$B,<ZP(*&*=AH8HKP%NC@B1Y0N."Q$8B@P04V9MAO(XP&6",,(^Z
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MH(*+I&0E+4FU#@Y-D@HX@>HN^4E0AE),)E 3#>M$AA7V8 VB9&4K75D5 S2
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)>^9SG]47$  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
